LES Foundation | LESI | Print Page | Contact Us | Sign In | Join
Speakers
Share |

LES 2013 Annual Meeting

Meeting Home | Schedule | Featured Speakers | Virtual Meeting | Presentations

Speakers

Robert Adelson, Managing Partner, Osage Partners
Shawn Ambwani, COO, Unified Patents
Jeffrey R. Anderson, JD, Registered Patent Attorney, Dunlap Codding P.C. 
Michael P. Arlotto, PhD, Global Vice President, Corporate Development, Quintiles
Rob Aronoff, Founder & Managing Partner, Pluritas
Jim Arthurs, President, Cummins Westport Inc.
Michael Attar, Executive Director, Business Development, Celgene
Phil Barnett, Managing Director, Phil Barnett LLC
Michael Barry, VP Licensing, Pachira Inc.
Keith Bergelt, CEO, Open Invention Network
Bryan Berger, Ph.D., Assistant Professor (Bioengineering and Chemical Engineering), Lehigh University
Liz Bhatt, Senior Director, Corporate Development, Gilead
Linda Biel, Senior Vice President Business Development, Allied Security Trust
Mark G. Bloom, CLP, CRCP, RTTP, Registered Patent Attorney, Director of Corporate Alliances and Technology Transfer (CATT), Bigelow Laboratory for Ocean Sciences
Barry Brager, Managing Partner, Perception Partners
Graham R. Brazier, Vice President, Business Development, Bristol-Myers Squibb Company
Roger Brooks, Partner, Cravath Swaine & Moore
Ger Brophy, Chief technology Officer, Life Sciences, GE Healthcare
Melanie L. Brown, Assistant General Counsel, BASF Corporation
Hector Chagoya, Partner, Director of IP Value Extraction, Becerril, Coca & Becerril
Hemmie Chang, Chair, Licensing & Strategic Alliances Practice, Foley Hoag LLP
Linda Chao, Senior Licensing Associate, Stanford University
Ivan Chaperot, Licensing & Patent Acquisitions, Intel
Margarita Chavez, Director, AbbVie Biotech Ventures
Peter Christensen, Commercialization Manager, Pacific Northwest Laboratory
Barbara Dalton, Ph.D., Vice President Venture Capital Worldwide Business Development & Innovation, Pfizer Ventures
Patricia Danzon, Professor, Health Care Management; Insurance and Risk Management, The Wharton School
Philip David, General Counsel, ARM Holdings
Todd Davis, Founding Managing Director, HealthCare Royalty Partners
Patrick Desmond, Sr. Manager Licensing, U.S. Gypsum Co.
Ian G. DiBernardoPartner, Stroock & Stroock & Lavan
Roberto Dini, Founder, Sisvel
Noah Doolittle, Senior Counsel, WW Businesses & Transactions, Kodak
Kathryn Doyle, Partner, Saul Ewing
Jane Eckels, Partner, Davis Wright Tremaine LLP
Ron Epperson, Managing Director, Intellectual Energy
Marc Erlich, Senior IP Counsel for Patent Enforcement, IBM Corp.
Mark Feingold, Associate General Counsel , University of Pennsylvania
Steven Ferguson, Deputy Director, Licensing & Entrepreneurship, NIH Office of Technology Transfer
Joel Feucht, General Manager, Caterpillar Inc.
Christine T. Fischette, Ph.D., Senior Advisor, Griffin Securities
Kerry Flynn, Vice President, Intellectual Property, Shire
Lance Follett, VP Corporate Development, Westport Innovations
Russ Gantt, Vice President, Regional &Corporate Business Development, AstraZeneca
Patrick Gattari, Partner, McDonnell Boehnen Hulbert & Berghoff LLP
Richard Gering, PhD, CLP, Principal, EisnerAmper LLP
Sian Godwin, Licensing Director, GE Healthcare
Klaus Göken, Patent Attorney, Partner, Eisenführ Speiser
Susan Goldsmith, Partner, SorinRand LLP
Anthony Green, Ph.D., Vice President, Technology Commercialization Group - Life Sciences, Ben Franklin Director - The Nanotechnology Institute and Energy Commercialization Institute, Ben Fraklin Technology Partners - SEP
Mike Gross, Senior Licensing Manager, Kimberly-Clark
Gary Haag, PhD, CLP, Contracts Consultant, ConocoPhillips
R. Mark Halligan, Partner, Nixon Peabody
John Hamann, Principal, Hamilton, Brook, Smith, Reynolds
Robert Heath, Senior Vice President of Corporate Development, RPX Corporation
Chris Hoecke, CEO, Mallard Research
Krista Holt, President & CEO, GreatBridge Consulting
Mark Horsburgh, Principal, Fisher Adams Kelly
Doug Hudson, Senior Patent Counsel, Google 
Kevin Jakel, CEO, Unified Patents
David Jarczyk, President & CEO, ktMINE
Mary Juetten, Founder & CEO, Traklight
Dina Kallay, Director, Intellectual Property & Competition at Ericsson, formerly from FTC
Tariq Kassum, Vice President, Business Development and Strategy, Millennium: The Takeda Oncology Company
Efrat Kasznik, President, Foresight
Paul Kerkhoven, Director, Government Relations, NGVAmerica
William Kerr, Director, Berkley Research Group
Scott Kieff, Fred C. Stevenson Research Professor of Law; Director of Planning and Publications, George Washington University, School of Law
Demetrios Kydonieus, formerly VP Strategy, Alliances and Transactions, Bristol-Myers Squibb
Ron Laurie, Managing Director, Syndicated Patent Acquisitions Corp.
Alan Leeds, Partner, Morgan, Lewis & Bockius LLP
Reid Leonard, Ph.D., Managing Director, Merck Research Ventures Fund, Executive Director, Worldwide Licensing and Acquisitions
Russell Levine, Partner, Kirkland & Ellis LLP
Traci Libby, Director, Corporate Development; Global Head of In-Licensing, Life Technologies Corporation
Scott Livingston, Chairman and CEO, Livingston Securities LLC
Jack Lu, Chief Economist and Senior Director for IP Market Advisory Practice (IPMAP), Applied Economics Consulting Group
Gene Lucadamo, Industry Liaison, P.C. Rossin College of Engineering, Lehigh University
Richard M. Ludwin, Associate General Counsel, IBM Intellectual Property Law

Kenneth Lustig, Vice President, Global Licensing, Intellectual Ventures
Timothy Lynch, Chief IP Officer, Kodak
Marc S. Malandro, PhD, CLP, RTTP, Associate Vice Chancellor for Technology Management and Commercialization, University of Pittsburgh
Michele Marcolongo, Ph.D., Sr. Associate Vice Provost for translational Research, Drexel University
Richard Marsh, General Counsel, Myriad Genetics
Cozette McAvoy, Senior Patent Attorney, Oncology Pharma Patents, Novartis
John McCauley, SVP, Strategic Alliances, Screenvision
Daniel McCurdy, CEO, Allied Security Trust
Thomas McGahren, Senior Managing Director, Investment Banking at Griffin Securities
Malcolm McGowan, Partner, Womble Carlyle Sandridge & Rice LLP
Thomas Meagher, Managing Partner, Meagher Emanuel Laks Goldberg & Liao, LLP
Luis Mejia, Senior Associate, Stanford University 
Claus Melarti, Vice Chair of MCE, Sony
Gayle Mills, Chief Business Officer, Symphogen
Raul Montes, Manager, Intellectual Property & Licensing, ExxonMobil Upstream Research Company  
Tanya Moore, General Manager, Business Development & Strategy, Microsoft
Nader A. Mousavi, Partner, Sullivan Cromwell LLP
Polly Murphy, Vice President, Specialty Care Business Unit BD, Pfizer
Charles Murray, Global Managing Director, DuPont
Alan Naidoff, Director, Licensing & Research Contracts, Merck Sharp & Dohme
Stephen G. Nappi, Associate Vice Provost for Technology Development and Commercialization, Temple University
Tom Needham, Partner, Advent Healthcare Ventures
Ada Nielsen, Managing Director, The PeregrineMaven Group
Brian O'Shaughnessy, Shareholder, RatnerPrestia
Deanna Okun, Partner, Adduci, Mastriani & Schaumberg, formerly Commissioner, ITC
Niklas Östman, Senior Director, IP Licensing, Microsoft
John Paul, Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Judith Paul, Manager, Technology Contracts, FMC Technologies, Inc.
Bob Payne, President, IP Licensing Advisors, LLC
Ruth Plager, President, ZenithBIO
Ellen Purpus, Director, The Children's Hospital of Philadelphia
Gerald Quirk, Partner, Choate, Hall & Stewart
Arti Rai, Elvin R. Latty Professor of Law, Duke University School of Law (Formerly Administrator of the USPTO Office of External Affairs)
Richard Rainey, Executive Counsel, IP Litigation, GE
Matthew Raymond, Director of IP, Rush University Medical Center
Eric Reifschneider, Sr. Vice President & General Manager, QUALCOMM Technology Licensing, QUALCOMM Incorporated
Stephen Reily, Managing Director & Chairman, IMC
Frank Reiner, Vice President Global Licensing, Kudelski Group
Michael Risch, Professor of Law, Villanova University School of Law 
Eric Risser, Vice President, Business Development, Macrogenics
Kathy Rosa, President, Shenandoah Consulting Services, LLC
Juli SaitzManaging Director, F T I  Consulting
Ed Saltzman, President, Defined Health
Michael Samardzija, Partner, Bracewell & Giuliani LLP
Julie Samuels, Staff Attorney and The Mark Cuban Chair to Eliminate Stupid Patents, Electronic Frontier Foundation
George SchoenPartner, Cravath, Swaine & Moore
Ekkehard Schoettle, Senior Counsel, BP America
Jeffrey Sears, Associate General Counsel and Chief Patent Counsel, Columbia University
Gail Shulman, (former General Counsel), MIPS Technologies
Laura Silva, Director, IP, Legal, and Licensing, Velocys, Inc.
Robin Sitver, Sr. Director Business Development, Johnson & Johnson Consumer Companies, Inc.
Jim Skippen, President & CEO, Wi-LAN Inc.
Catherine Angell Sohn, Pharm.D., President, Sohn Health Strategies
Wayne Sobon, VP & General Counsel, Inventergy 
John Somich, Intellectual Asset Strategist, BP
Erich Spangenberg, Owner, IPNav
Karen Stevenson, Licensing Associate, University of Idaho Office of Technology Transfer
Debora Stewart, Managing Director, Invotex
Mark Stignani, Of Counsel, Schwegman, Lundberg & Woessner
Lesley Stolz, Vice President, Business Development, Sutro Biopharma
Phil Strassburger, Vice President, IP Counsel, Purdue Pharma LP
Hamza Suria, President & CEO, AnaptysBio
William Tanenbaum, Partner, Chair, IP and Technology Transactions Group and Green Tech and Sustainability Group, Kaye Scholer
Laurie Tzodikov, Sr. Licensing Associate, Office of Technology Licensing, Princeton University
Shashank Upadhye, Partner, Seyfarth Shaw, LLP (Formerly Global Head of IP Apotex Inc. and U.S. Head of IP Sandoz
Guy Van Meter, Vice President, Head of Business Development, Adimab
Allen Vaughn, Manager of IP Strategy and Licensing, Lockheed Martin
David Wallan, Director, Intellectual Property and Licensing, DuPont
Aric Weiker, Director, Business Development and Strategy, Microsoft
Jeffrey Whittle, Partner, Bracewell & Giuliani LLP
Nick Widnell, Deputy Assistant Director, Bureau of Competition's Anticompetitive Practices Division, Federal Trade Commission
Joff Wild, Editor, IAM Magazine
Clint Wilder, Senior Editor, Clean Edge
Michael Williams, Team Lead, Commercial Sectors LNG for Transport, Shell Americas
Scott WilliamsDirector, Invotex
Timothy Wilson, Senior IP Counsel, SAS Institute
Henry Wixon, Chief Counsel, NIST
David Woodle, CEO and Chairman, NanoHorizons
Barbara Yanni, Vice President and Chief Licensing Officer, Merck

Robert Adelson, Managing Partner, Osage Partners
Bob founded Osage Partners in 1990 and has built a track record as a top-performing venture investor. He is a native of Tulsa, Oklahoma, where he is a partner in a fourth generation family business. Prior to founding Osage, Bob clerked with the honorable Walter K. Stapleton, U.S. Third Circuit Court of Appeals, and practiced corporate law at the Philadelphia law firm of Wolf, Block, Schorr & Solis-Cohen. Bob’s previous venture investments include Zany Brainy, Inphonic, Internet Capital Group (NASDAQ: ICGE), and GHR Systems (acquired by Metavante). He is a graduate of The Yale Law School, where he was an editor of The Yale Law Journal, and of Yale College, from which he graduated summa cum laude. Bob is a trustee of Thomas Jefferson University Hospital, Thomas Jefferson University, and Jefferson Health System. He is also a former President of the Board of Trustees of The Philadelphia School and a past member of The Yale Law School Fund.

Bob currently serves on the boards of SevOne, Halfpenny Technologies and Collections Marketing Center.

Bob and his wife Marta reside in Merion, PA. They have three children.

[back to top]

Shawn Ambwani, COO, Unified Patents
Shawn AmbwaniShawn is COO of Unified Patents. Responsible for sales, marketing, and operations. He is Chair-elect of Licensing Executives Society (LES) US / Canada - High Tech Sector (HTS). An accomplished software and intellectual property executive and successful entrepreneur whose last 2 startups went IPO.

Previously he was VP of Licensing and Business Development at Intertrust Technologies, Inc. responsible for patent and technology licensing programs with over $500 million in revenue. ;In the past, he was EVP at Nextreaming (KOSDAQ) - where he was General Manager of their Platform Division, an enterprise media software solution, before being sold to Hutchison. He also co-founded Envivio (NASDAQ; ENVI), which was spun off from France Telecom in 1999 to develop MPEG-4 streaming solutions for the broadcast, cable network, and content developer markets. At France Telecom, he conceived and led international teams in the development of Internet services in France and in the US. He has a Math degree from UCLA and JD/MBA from Boston University. He is a member of the California Bar.

[back to top]

Jeffrey R. Anderson, JD, Registered Patent Attorney, Dunlap Codding P.C.
Jeffrey AndersonJeff Anderson practices in all areas of intellectual property, with an emphasis on managing IP portfolios, negotiating complex intellectual property transactions and agreements, and drafting and prosecuting patent applications. His technology background includes chemistry and engineering. Jeff gained significant field experience as an engineer before attending law school.

Jeff served as the sole in-house counsel at KiOR, Inc., a next generation renewable fuels company, and was responsible for managing the company's trademark and patent portfolio and worked with the VP of R&D to establish and execute an IP and research strategy plan. Jeff served as an in house counsel for ConocoPhillips and negotiated complex, multi-million dollar, intellectual property transactions including research and technology in-licensing, served as the sole attorney supporting two major licensing programs, prepared and prosecuted multiple patent applications, and oversaw {and prepared) infringement, validity, and freedom-to-operate opinions in support of business unit objectives.

[back to top]

Michael P. Arlotto, PhD, Global Vice President, Corporate Development, Quintiles
Michael ArlottoMike Arlotto is global vice president for Quintiles Corporate Development responsible for transformational partnerships and strategic relationships.  Earlier in his career with Quintiles, handled projects for all North American Clinical Development Services, managing a staff of about 250 research professionals in multiple locations in the U.S. and Canada. Mike also managed the Proposals, Pricing and Contracts groups.

Prior to joining Quintiles in 1997, was a research scientist with Bayer Corp., where he implemented an in vitro metabolism laboratory.He also held the position of Director of Scientific Planning and Development at Dallas Biomedical, a venture capital-backed company that commercialized novel technologies from universities.

Previously, as a Research Scientist, worked on the application of recombinant enzymes for in vitro drug metabolism and toxicology testing, among other projects. Mike has published dozens of abstracts and articles in research journals and patented a generation of radioactive oxidation products.

Mike earned his Bachelor of Sciences degree in Toxicology, at the Philadelphia College of Pharmacy and Science, and a Ph.D. in Toxicology at Kansas University.

[back to top]

Robert Aronoff, Founder & Managing Partner, Pluritas
Robert AronoffRobert Aronoff leads Pluritas, a firm that specializes in the buying and selling of intellectual property assets. Rob has more than twenty-five years' experience. He has worked as an executive or management consultant at Sun Microsystems (now part of Oracle), Eastman Kodak, Microsoft, Coopers & Lybrand and Peat Marwick.

While at Kodak he served as founding Executive Director of the Digital Imaging Group, a still active industry consortium. Prior to establishing Pluritas, Rob was Managing Partner of Worldwide Capital Partners, a San Francisco based advisory firm and predecessor to Pluritas.

Rob holds B.A.'s in Computer Science and Economics from Brandeis University, where he was a Milton Feld Economics Scholar, and an M.B.A. from the M.I.T. Sloan School of Management, where he was awarded the William L. Stewart Award for Outstanding Contributions to the University. He is a member of the IAM 250 – The World's Leading IP Strategists.

[back to top]

Jim Arthurs, President, Cummins Westport Inc.
Jim Arthurs is President of Cummins Westport Inc., a joint venture company owned by Cummins Inc. and Westport Innovations Inc. that develops and sells medium- and heavy-duty natural gas engines for commercial transportation applications such as trucks and buses.  Prior to joining Cummins Westport in February 2012, Jim was Vice President, Cryogenic Systems for Westport Innovations and previously was Vice President, Operations for Westport HD. Over his career, Jim has held senior sales, operating and management positions at several companies including IBM and Weyerhaeuser. He is a member of the board of directors and chairman of the audit company of Western Forest Products Inc., an integrated forest products company. He is also a member of the board of directors of NGVAmerica. Jim holds a BSc degree in Computer Science from the University of Calgary.

[back to top]

Michael Attar, Executive Director, Business Development, Celgene
Michael joined Celgene's Business Development team following the company's acquisition of Abraxis BioScience in the fall of 2010. In the 2+ years Michael has been with Celgene, he has taken the lead from a BD perspective in putting in place the company's biologics collaborations, including deals announced with AnaptysBio, Inhibrx and Sutro Biopharma. Michael joined Abraxis in early 2008, and among other accomplishments, helped establish the Abraxis commercial presence in China and helped lead the commercial launch of Abraxane in that market. Prior to joining Abraxis, Michael was involved in the tech\telecom area, working for two technology companies in southern California. Prior to these engagements, Michael was a sell-side Research Analyst at Morgan Stanley covering the wireless telecom space. Michael received his undergraduate degree from the Johns Hopkins University and his MBA from the Kellogg School of Management at Northwestern University.

[back to top]

Phil Barnett, Managing Director, Phil Barnett LLC
Phil BarnettPhil Barnett consults with clients in projects focused on intellectual property risk issues and effective enterprise knowledge management (KM).  He works both domestically and internationally, designing and developing high impact organizations and processes that help companies grow customer impact and revenue.  Phil has delivered successful projects in a wide range of sectors including professional/legal services,  education,  healthcare, consumer products, OEM automotive, chemicals, oil & gas, government and non-profits.

Phil is former Managing Director for PwC, serving clients from its Assurance, Tax and Advisory practices as an IP and KM specialist.  He also worked internally for the partnership as Strategy & Operations Leader for its Knowledge Services Organization (KSO) and guided the implementation of its design, change management, learning & development, budget, project management, value reporting and culture change.  Collaborating with inside counsel, he supported  internal audits of PwC's own intellectual property and  knowledge management process areas and advised the firm with respect to IPM/KM integration from its acquisitions.

Phil served the Licensing Executive Society - USA and Canada as Vice President of Education and Vice President for Local Chapters.  He is a 2013 member of The World's Leading IP Strategists (IAM300) selected by IAM Magazine.

[back to top]

Michael Barry, VP Licensing, Pachira Inc.
Michael BarryMike was formerly Vice President of Intellectual Property and General Patent Counsel for AmberWave Systems Corp., an MIT-spinout engaged in commercial R&D of semiconductor materials, where he was responsible for all IP matters. Prior to that he was General Counsel of TARGUS Information Corp., a leading supplier of real-time, network-based information services. While with TARGUS he also was president of Murex Licensing Corp., an affiliated patent licensing company, where he successfully developed and executed a licensing program for patents related to the TARGUS technology. Also previously he was Patent Counsel for Samsung Electronics, where he had a lead role in patent license negotiations and litigation involving telecommunication and semiconductor technologies.

Mike started his career as an attorney with the Indianapolis-based law firm of Barnes & Thornburg, where he worked on a wide spectrum of IP matters, primarily in the areas of patent litigation and prosecution. Prior to that he worked as an engineer, including 12 years in various avionic/electronic engineering positions with McDonnell Douglas.

Mr. Barry graduated from the Saint Louis University School of Law, magna cum laude, in 1996. He received his B.S.C.E. and M.S.E.E. degrees from Washington University in St. Louis.

[back to top]

Bryan Berger, Ph.D., Assistant Professor (Bioengineering and Chemical Engineering), Lehigh University
Bryan BergerBryan W. Berger received his B.Sc. degree in chemical engineering from the University of Illinois at Urbana-Champaign in 1999; during that time he was a DAAD academic exchange scholar at the Institute for Physical and Theoretical Chemistry at the Technical University of Garching in Germany. He spent a brief time working as a product engineer in the Hospital Products Division of Abbott Laboratories before returning to graduate school, receiving his Ph.D. in chemical engineering from the University of Delaware in 2005. From 2005 to 2009 Bryan was a NIH NRSA postdoctoral fellow at the University of Pennsylvania School of Medicine before joining Lehigh University as an assistant professor of chemical engineering and bioengineering in 2010. Bryan has received a 2012 NSF BRIGE award, a 2013 NSF EFRI award and a 2013 TechConnect National Innovation Award. His work spans a range of diverse topics, including protein engineering, biosurfactant design, and scalable biosynthesis of nanomaterials.

[back to top]

Liz Bhatt, Sr. Director, Senior Director, Corporate Development, Gilead
Liz Bhatt is a Senior Director, Corporate Development at Gilead Sciences where she is responsible for licensing, merger and acquisition activities across the company's various therapeutic areas.  She joined Gilead in June 2006, and in addition to executing deals in corporate development, she was also Senior Director, Commercial Strategy leading global commercial and strategic planning for Gilead's antiviral and respiratory franchises. Before Gilead, Ms. Bhatt held corporate development and strategy roles at Maxygen and Eli Lilly. She holds a B.A. in chemistry from Pomona College, a M.S. in Biomedical Sciences from University California, San Diego and an M.B.A. from the Kellogg School of Management at Northwestern University.

[back to top]

Linda Biel, Senior Vice President Business Development, Allied Security Trust
Linda BielLinda Biel has more than 20 years of experience in high technology, specializing in business development, marketing and sales.  She is responsible for new member recruitment and the management of relationships between Allied Security Trust and sellers of patent portfolios, including patent brokers and direct sellers. She also handles the sales of portfolios that AST has purchased, once involved members are licensed. Previously, she was a founder and Director of Customer Relations for PatentFreedom, and before that served in a variety of customer and partner interfacing roles as a Director at IBM, including assignments in both Asia and Europe. Linda received a M.S. magna cum laude in Industrial Engineering from Texas A&M University.

[back to top]

Mark G. Bloom, CLP, CRCP, RTTP, Registered Patent Attorney, Director of Corporate Alliances and Technology Transfer (CATT), Bigelow Laboratory for Ocean Sciences
Mark BloomMark Bloom, CLP, RTTP™, is the Director of Corporate Alliances and Technology Transfer for Bigelow Laboratory for Ocean Sciences (East Boothbay, Maine).  Mark is an internationally-recognized intellectual property attorney and academic technology transfer professional.  Prior to joining Bigelow Laboratory, Mark worked for Cleveland Clinic Innovations and the University of Wisconsin-Madison.

Among other professional activities, Mark is Editor of the AUTM Technology Transfer Practice Manual, a four-volume treatise focused on academic technology transfer, and is Chair-elect of the Industry-University-Government Interface (IUGI) Sector of LES - USA & Canada.  Mark is a Registered Patent Attorney and is also an Adjunct Professor of Law at the University of New Hampshire School of Law's Franklin Pierce Center for Intellectual Property.

Before attending the UNH School of Law, Mark worked in sales and marketing for the pharmaceutical and biomedical device industries.

Mark brings more than twenty-six years of business and legal experience to Bigelow Laboratory.

[back to top]

Barry Brager, Managing Partner, Perception Partners
Barry BragerBarry is a Certified Licensing Professional and the Founder and Managing Partner of Perception Partners®. He leads a research organization that systematically addresses questions of competitive landscapes, white spaces, open innovation, IP transactions and litigation. Barry has directed the analysis of more than a half-million patented technologies worldwide and has supported decisions related to billions of dollars in IP and technology transactions.

Since 2009, Barry has been recognized each year as one of the world's Leading IP Strategists as part of the global IAM300, published by IAM Magazine. Barry currently serves on the IPO Corporate IP Management Committee and has previously served two terms as the IPO Small Business Committee Chair. Barry has also been a co-chair of the Licensing Executives Society USA-Canada Annual Meeting. Barry is a frequent speaker on IP strategy, valuation and the links between patent intelligence and competitive advantage. Barry holds an M.B.A. from Emory University, graduating Beta Gamma Sigma and first in his class.

[back to top]

Graham R. Brazier, Vice President, Business Development, Bristol-Myers Squibb Company
Graham BraizerGraham joined Bristol Myers Squibb in 2002 and has transactional responsibility for the full array of collaborations covering research, clinical and commercial stage assets across BMS' global pharmaceutical business. Graham is also responsible for Japan Partnering activities.

Prior to joining BMS, Graham was Senior Vice President, Corporate Development at 3-Dimensional Pharmaceuticals, a drug discovery company and before that Vice President, Worldwide Business Development at SmithKline Beecham Pharmaceuticals, where he spent 10 years.

Graham has successfully led and overseen numerous transaction teams involved in company acquisitions, co development and co promotion deals, compound in and out licensing, product disposals, research collaborations, patents licenses and other strategic transactions.

Originally from the UK, Graham has lived and worked in Holland, Belgium and the USA, where he has spent the last 18 years.

Graham is a fellow of the Chartered Association of Certified Accountants, United Kingdom.

[back to top]

Roger Brooks, Partner, Cravath Swaine & Moore
Roger BrooksRoger Brooks is a partner in Cravath's Litigation Department.  His practice covers a wide range of technology-intensive courtroom litigation, including disputes concerning patents, licensing, and technology-related antitrust claims.

Mr. Brooks is an expert in antitrust issues relating to standardized technologies and "FRAND" licensing.  He is lead counsel for Qualcomm defending against antitrust claims arising from the development of the "LTE" cellular standard, and was previously lead counsel for Qualcomm in FRAND-related litigation against Nokia.  Mr. Brooks co‑authored the chapter "Taking Contracts Seriously: The Meaning of the Voluntary Commitment to Licence Essential Patents on ‘Fair and Reasonable' Terms," in Intellectual Property and Competition Law: New Frontiers (Oxford University Press), and authored the article, "Patent ‘Hold‑Up,' Standards-Setting Organizations and the FTC's Campaign Against Innovators," published in the AIPLA Quarterly Journal (Fall 2011).  Mr. Brooks received his A.B. from Princeton University in 1984, and his J.D. from the University of Virginia in 1987.

[back to top]

Ger Brophy, Chief technology Officer, Life Sciences, GE Healthcare
Ger Brophy

Ger Brophy is Chief technology Officer of Life Sciences GE Healthcare; responsible for technology strategy in the Research and Diagnostic tests space.

Prior to this Ger was head of New Product Development for Medical Diagnostics in GE Healthcare, responsible for the overarching R&D strategy encompassing in vivo and in vitro diagnostic technologies; overseeing discovery (research) and clinical development; regulatory and medical affairs; project and portfolio management; product acquisition and licensing; R&D efficiency projects and collaborations across GE.

Previously, Ger led Strategic Planning & Licensing within Medical Diagnostics business. He was centrally involved in the expansion of the business into the Personalized Medicine space through inorganic and organic investments in in vitro diagnostics and pathology.

Before joining the Medical Diagnostics business, Ger ran the Life Sciences Advanced Systems business in Sweden.  The focus on that business was in the commercialization of improved tools for drug discovery.  In that capacity he lead an R&D group of 200 researchers developing new products and services used in academia and Pharma to better understand disease. 

Ger began his career in R&D developing high throughput drug screening tools.  He advanced to become Development Director for Amersham's Bioassay's business unit, leading a group of 60 people.  Within GE Healthcare he has held positions in Licensing, Business Development and R&D.

Ger has had international assignments in the UK, Sweden and in Chicago & New Jersey. He is based in London, UK. 

Ger holds a Ph.D. in Molecular Biology.

[back to top]

Melanie L. Brown, Assistant General Counsel, BASF Corporation
Melanie BrownMelanie Brown has been with BASF Corporation (previously Engelhard Corporation) for 10 years and is an IP group leaderJn the BASF Legal Department. Since June 2007, Melanie has been responsible for the global IP matters of the Environmental Catalysts business including patent procurement, defense, and enforcement including licensing. Melanie was also responsible for the successful integration of the Engelhard and Ciba IP estates into BASF.

Melanie is the Pro Bono Coordinator for BASF, earned the Individual Volunteer of the Year Award from the Pro Bono Partnership in 2011, and contributed to BASF winning the Corporate Volunteer of the Year Award from the Pro Bono Partnership in 2012. Melanie earned a Bachelor of Science degree in Materials Engineering from Rensselaer Polytechnic Institute and a Juris Doctorate with honors from Capital University Law.School. She is licensed to practice before the US Patent and Trademark Office and in Ohio and New Jersey.

[back to top]

Hector Chagoya, Partner, Director of IP Value Extraction, Becerril, Coca & Becerril
Hector ChagoyaHector Chagoya, Partner and Director of Patents & Technology at BC&B. With an IP experience since 1997, he holds the CLP credential (first in Mexico) and has been recognized as a leading patent practitioner in leading international guides. Currently in charge of consulting services for leveraging value from IP assets, in addition to leading the patent prosecution practice in his firm, he leads working teams through technology intelligence studies, IP assets valuation, IP negotiations, technology evaluation and the analysis of substantive issues of patent litigation. He is recognized by the National College of Chemical Engineers and Chemists (CONIQQ) as expert in Engineering Economy, of which he is also teacher in the Chemical Engineering program at Universidad La Salle. He has also acted as expert witness for the substantive issues of several patent litigation cases. He has published a variety of articles in specialized international magazines of Intellectual Property and Technology Licensing, and is co-author of chapters in various books related to licensing, trade secrets and pharmaceutical law and practice. He is President of LES Mexico and Vice- President of LES International; Past-President of the Mexican Institute of Chemical Engineers (Mexico City Chapter), and of AIPPI and INTA amongst other professional associations in Mexico and abroad.

[back to top]

Hemmie Chang, Chair, Licensing & Strategic Alliances Practice, Foley Hoag LLP
Hemmie ChangHemmie Chang Chairs the Licensing & Strategic Alliances Practice Group at Foley Hoag LLP. where she focuses on complex collaboration and licensing transactions. She has over two decades of experience advising both large partners and emerging companies on IP transactions, including the licensing of assets from academic institutions. Hemmie recently completed an early stage research collaboration for CytImmune of its nanotechnology platform with AstraZeneca and previously represented Metamark Genetics in its $365 million collaboration with Janssen Biotech. She has also advised start-ups in the medical device and alternative energy technology fields in equity co-investment and collaborations with major partners.

[back to top]

Ivan Chaperot, Licensing & Patent Acquisitions, Intel
Ivan ChaperotIvan Chaperot is responsible for strategic and large scale patent acquisitions and licensing transactions at Intel Corporation, a position he has held since November 2011. Before this role, he was a Licensing Executive at Intellectual Ventures, managing and licensing a $100M+ patent investment portfolio relating to software technologies. Before that, as a Senior Manager at Alcatel Lucent, he developed the first successful outbound patent sales and licensing program, generating over $50M of incremental revenues. In 2007, Mr. Chaperot worked with former members of Lucent Technologies New Ventures Group to develop spin out companies based on corporate research and VC financing. He has authored and lectured on financial valuation and licensing activities, in particular, real-option valuations for complex IP transactions. Mr. Chaperot is a European Patent Attorney and a French Patent Attorney.

[back to top]

Peter Christensen, Commercialization Manager, Pacific Northwest Laboratory
Peter is a commercialization manager with responsibility for identification , protection, and management for the Pacific Northwest National Laboratory's growing energy portfolio. Peter is also the team lead for PNNL's technology commercialization group and is responsible for leading and coordinating the Laboratories technology transfer strategies and activities.

Prior to joining PNNL, Peter worked as a patent attorney and as a VP of engineering for a leading PEM fuel cell developer.  Known as a national expert on competitive power markets, Peter has also worked for an energy consulting company where he helped large industrial users prepare for and take advantage of the increasingly complex and changing electrical power markets.

Peter holds a Bachelor of Science degree in electrical engineer ing from the University of Minnesota and a juris doctor from the University of New Hampshire School of Law (formerly Franklin Pierce Law Center) in Concord, New Hampshire

[back to top]

Barbara Dalton, Ph.D., Vice President Venture Capital Worldwide Business Development & Innovation, Pfizer Ventures
Barbara DaltonDr. Dalton is responsible for Pfizer's Venture Investments, managing the current private equity portfolio and advising on equity transactions.  Dr. Dalton was a founding member of EuclidSR Partners, a private venture capital firm. She began her business career as a research scientist at SmithKline before moving to their venture capital subsidiary, S.R. One, Limited. Barbara has managed diverse fund and company investments throughout the world. She is an advisor to the Dean of the Penn State Eberly College of Science, where she received her undergraduate degree, and a member of The Penn State Research Foundation Board of Directors. She leads the Healthcare Investing Group of the New York City Investment Fund and is a former member of the Board of Directors of the Alzheimer's Disease Research Foundation, NY Biotech Association and the National Venture Capital Association. Dr Dalton received her PhD in Immunology and Microbiology from The Medical College of Pennsylvania.

[back to top]

Patricia Danzon, Professor, Health Care Management; Insurance and Risk Management, The Wharton School
Patricia Danzon is the Celia Moh Professor at The Wharton School, University of Pennsylvania. Professor Danzon received a B.A. from Oxford University, England, and a Ph.D. in Economics from the University of Chicago. She has held faculty positions at Duke University and the University of Chicago.

Professor Danzon is an internationally recognized expert in the fields of economics of health care, the biopharmaceutical industry, and insurance.  She is a member of the Institute of Medicine and the National Academy of Social Insurance, and a Research Associate at the National Bureau of Economic Research. She has served as a consultant to many governmental agencies, NGOs and private corporations in the US and internationally. Professor Danzon has served on the Board of Directors of Medarex, Inc., the Policy and Global Affairs Board of the National Academy of Sciences, and the Policy Board of the Office of Health Economics in London.

Professor Danzon has been an Associate Editor of the American Economic Review, the Journal of Health Economics and the International Journal of Health Care Finance and Economics. She has published widely in scholarly journals on a broad range of subjects related to health care, pharmaceuticals, biotechnology, insurance, and the economics of law. She co-edited the Handbook on the Economics of the Biopharmaceutical Industry (2012), for Oxford University Press. Selected publications include: "Exits from Vaccine Markets in the US: The Role of Competition vs. Regulation" (with N. Pereira), International J. of the Economics of Business 2011; "Setting Cost-Effectiveness Thresholds As A Means To Achieve Appropriate Drug Prices In Rich And Poor Countries" (with A. Towse and A. Mulcahy) Health Affairs 2011; "Drug Pricing and Value in Oncology" (with E. Taylor) The Oncologist 2010; "Productivity in Pharmaceutical-Biotechnology R&D: The Role of Experience and Alliances" (with S.Nicholson and N.Pereira) J. of Health Economics 2005; "Biotech-Pharma Alliances as a Signal of Asset and Firm Quality" (with S. Nicholson and J. McCulloch, J. of Business 2005.

[back to top]

Philip David, General Counsel, ARM Holdings
Philip David is General Counsel at ARM, the world's leading designer of microprocessors for portable devices. He is a member the executive committee and has nearly 20 years' experience in the field of intellectual property (IP) law and helped ARM develop its IP protection and exploitation strategies.

[back to top]

Todd Davis, Founding Managing Director, HealthCare Royalty Partners
Todd DavisMr. Davis is a Founding Managing Director and member of the Investment Committee at HC Royalty. He brings particular expertise in the commercial, operational and licensing aspects of potential investments. Mr. Davis has been involved in over $2 billion in healthcare deals including sourcing, conducting due diligence, and leading nearly $1 billion in royalty financings. He has led, structured and closed over 40 additional intellectual property licenses, as well as growth equity, and debt deals. In addition, Mr. Davis spearheads the firm's global business development efforts and coordinates the firm's public relations activities. Previously, Mr. Davis was a partner at Paul Capital Partners, where he co-managed that firm's royalty investments as a member of the royalty management committee. He also served as a partner responsible for biopharmaceutical growth equity investments at Apax Partners. Prior to beginning his principal investment career in 2001, Mr. Davis held various sales and product management roles at Abbott Labs and worked in business development, operations and licensing at Elan Pharmaceuticals. Mr. Davis holds a BS from the U.S. Naval Academy and an MBA from Harvard University. He currently serves on the boards of Ligand, Nuron Biotech and Suneva Medical.

[back to top]

Ian G. DiBernardo, Partner, Stroock & Stroock & Lavan  
Ian G. DiBernardoIan G. DiBernardo counsels both emerging and established companies on intellectual property and Internet law, focusing on complex intellectual property and technology transactions and intellectual property litigation.

Mr. DiBernardo's transactional practice includes structuring and negotiating a variety of agreements, including outsourcing, cloud computing, license, distribution and joint venture agreements. In addition, he negotiates and conducts due diligence on the intellectual property and information technology aspects of a broad range of corporate transactions, including mergers and acquisitions, joint ventures and securities and corporate finance transactions. As part of his transactional practice, Mr. DiBernardo frequently counsels clients on data protection and privacy issues.

Mr. DiBernardo also works closely with Stroock's financial services and capital markets clients, structuring and negotiating market access, electronic trading, and dark pool agreements, as well as licenses to financial indexes, market data, risk management software, back office systems and other trading technologies.

As a litigator, Mr. DiBernardo has first-chair trial and appellate litigation experience, representing both plaintiffs and defendants in patent, trade secret and copyright matters. He has also successfully argued before the U.S. Court of Appeals for the Federal Circuit.

Mr. DiBernardo has particular experience with financial products and systems, consumer electronics, Internet technologies and medical devices and systems.

[back to top]

Roberto Dini, Founder, Sisvel
Roberto DiniWith more than 40 year of experience, Roberto Dini is one of the best known and appreciated Intellectual Property experts. He began his career with Indesit where he was Head of the Patent and Trademark Office.

In 1982 Mr. Dini founded Sisvel, which has soon become a world leader in managing Intellectual Property and maximizing the value of patent rights.

In 1987 Mr. Dini founded Metroconsult, an Intellectual Property consultancy firm, wherein he transferred the experience acquired from the industrial world, providing his clients with high-quality services "tailored" to the needs of each individual client.

Mr. Dini is a Member of the Italian Industrial Property Consultant Association, a registered Patent Attorney before the European Patent Office (EPO) and Trademark and Design attorney before the Office for Harmonization in the Internal Market (OHIM).

Mr. Dini is currently the president of LES (Licensing Executives Society) Italy.

[back to top]

Noah Doolittle, Senior Counsel, WW Businesses & Transactions, Kodak
Noah DoolittleNoah Doolittle is now Senior Counsel, WW Businesses & Transactions, at Eastman Kodak Company.

Mr. Doolittle joined Kodak in 2008 to work in Kodak’s IP Transactions group, principally in patent licensing.  He had increasing responsibilities within that group, becoming Senior Counsel, Vice President IP Transactions, a position held until Kodak recently eliminated the group.  Prior to joining Kodak, Mr. Doolittle was at Nixon Peabody LLP.

Mr. Doolittle holds a J.D. from the University Of Virginia School Of Law and went to Boston College for his undergraduate studies.  He is a member of the New York State Bar.

[back to top]

Jane Eckels, Partner, Davis Wright Tremaine LLP
Jane EckelsJane Eckels is a partner at Davis Wright Tremaine LLP , where she is a deputy chair of its Technology, Advertising, Trademark and Entertainment group and focuses her practice on information technology and intellectual property transactions. With over 15 years of experience, Jane has drafted, negotiated and advised on hundreds of deals involving software, hardware and Internet technologies, as well as data and content.  Her extensive experience includes licensing and acquisitions; development projects; ecommerce; implementation, consulting and other professional services; support and maintenance; and hosting and outsourcing services. She has real-world experience working with companies ranging from start-ups to multinational organizations to strategize, structure and realize complex IP licenses and commercial agreements.

[back to top]

Marc Erlich, Senior IP Counsel for Patent Enforcement, IBM Corp.
Marc EhrlichMarc is Senior IP Counsel for Patent Enforcement at IBM Corp., He manages the patent licensing and sales legal team responsible for generating IP income for IBM. In support of IBM's annual attainment of over $1B in IP income, the team focuses on the development and deployment of innovative patent monetization strategies including managing creation and presentation of infringement and sales collateral. Marc's previous IP management responsibilities have included oversight of the IP law department for IBM's semiconductor business and the patent portfolio management group tasked with the development and management of IBM's global patent portfolio. Prior to assuming these management roles Marc was a member of IBM's corporate IP licensing team where he negotiated patent cross licenses and other IP agreements for the company. He also served on IBM's Systems and Watson Research IPLaw teams addressing the general IP needs of those business clients including prosecution, litigation, technology licensing, and general advice and counsel.

Throughout his career Marc has been actively involved in developing and deploying IP strategy at IBM including IBM's founding role in the Peer to Patent project (enacted as law as part of the AIA), IBM's open source and other patent pledges, amicus activity at the Federal Circuit and the Supreme Court as well as co-developing the "Innovation Cycle" approach to IP management that informs IBM's balance of open and proprietary innovation.

Marc holds a BS degree in Geological Science from Binghamton University, a BSEE cum laude  in Electrical Engineering and Computer Science from Stevens Institute of Technology and a J.D. cum laude from Pace University School of Law.

Marc currently serves as the Chair of the Lawyer's Committee for Open Invention Network and as a member of the Legal Affairs Committee for OpenStack.

[back to top]

Mark Feingold, Associate General Counsel, University of Pennsylvania
Mark FeingoldMark Feingold is an Associate General Counsel at the University of Pennsylvania, responsible for helping prepare and negotiate business transactions at the University of Pennsylvania Health System, including technology transactions and the acquisition of physician practices. Among other things, Mark supports the Penn Medicine Center for Innovation (which facilitates innovation within the Health System and the School of Medicine). Prior to working for Penn, Mark was a transactional counsel with Merck and sanofi aventis, supporting the in/out-licensing of compounds, products and R&D tools as well as the divestiture of pharmaceutical products. Mark helped implement multi­ national agreements and resolve disputes. Mark also served as a regulatory/commercial attorney with Aventis (supporting its two largest products), was a Deputy Attorney General in New Jersey and began his career at the United States Department of Labor. Mark received his law degree from The American University and his undergraduate degree from the Pennsylvania State University.

[back to top]

Steven Ferguson, Deputy Director, Licensing & Entrepreneurship, NIH Office of Technology Transfer
Steven FergusonSteven M. Ferguson currently serves as a Deputy Director and senior licensing professional for the NIH Office of Technology Transfer, the patent & licensing office for technologies arising from the NIH and FDA research programs.

A former chemist at the National Cancer Institute, he holds Master's Degrees in Business Administration (George Washington University) and Chemistry (University of Cincinnati) as well as Bachelor's Degree in Chemistry (Case Western Reserve University).

A registered Patent Agent and Certified Licensing Professional, Mr. Ferguson is Technology Transfer Department Chair at the Foundation for Advanced Education in the Sciences (FAES) Graduate School at NIH. He has published numerous articles on licensing and technology transfer and is an Executive-in-Residence at Johns Hopkins University Cary School of Business.

He has received the AUTM President's Award and NIH Director's Awards, the FAES Instruction Award, the Federal Laboratory Consortium STEM Award and thirteen NIH Merit Awards in recognition of his service and activities in the area of technology transfer.

[back to top]

Christine T. Fischette, Ph.D., Senior Advisor, Griffin Securities
Christine T. Fischette, Ph.D.Christine T. Fischette, Ph.D. is Senior Advisor at Griffin Securities, NY, a boutique investment banking firm, and President/CEO of her own Business Development Consulting firm. She is on Advisory Boards for Genmedica and Xhale, Chair of the M&A Committee for the Licensing Executive Society (LES) and Board member for the LES NY Chapter. Formerly she was President of Enzo Therapeutics, Inc., a division of Enzo Biochem (ENZ:NYSE). Previously she spent 25+ years at Roche, Pfizer and Novartis with increasing areas of responsibility covering multiple therapeutic areas of research, drug development, commercialization and business development. During her tenure at Pfizer she directed the entire drug development process and subsequent marketing effort for an antidiabetes therapy, Glucotrol XL, bringing sales to ~ $350m. She conducted research as Senior Scientist at Hoffmann-La Roche and at Rockefeller University. Dr. Fischette holds a Ph.D. (Physiology) from UMDNJ. She has authored over 50 publications in peer-reviewed publications, including Science.

[back to top]

Lance Follett, VP Corporate Development, Westport Innovations Inc.
Lance, who leads the Corporate Development team at Westport, is a seasoned licensing professional in natural gas transportation having concluded numerous deals with major OEM's, suppliers and fuel providers. Lance has been with Westport since 2001 initially as IP Counsel and then in Corporate Development functions since 2005. Also a former Patent Litigator with Gowlings, Lance has been an LES member since 2003.

[back to top]

Russ Gantt, Vice President, Regional &Corporate Business Development, AstraZeneca
Russ GanttRuss is responsible for late stage global licensing transactions, large corporate acquisitions, divestments, and partnering such as joint ventures. The geography of his business development activities includes many countries across Central & Eastern Europe, the Middle East and Africa, Asia Pacific, Latin America, and Japan. It also includes Europe and North America.

Russ joined Astra Merck in 1997 as Business Development Executive. Previously, at Wyeth & Schering-Plough Russ held various positions in business development.. He started his career in vaccine manufacturing.

Russ has extensive expertise in acquisitions, divestments and strategic partnering.

Russ holds BS degree in Microbiology from the University of Tennessee.

[back to top]

Richard Gering, PhD, CLP, Principal, EisnerAmper LLP
Richard Gering Richard Gering Ph.D. is a Principal in the firm's Litigation Services Group.  He has over 25 years of experience providing economic, statistical and financial consulting services to attorneys and corporate clients. Richard has served as an economical damages expert witness in federal and state courts, as well as in arbitrations.

Prior to joining EisnerAmper, Richard spent over 20 years with a Big Four and then a regional accounting firm. He specializes in providing consulting and expert witness assistance including economic and statistical analysis related to commercial disputes. Richard assists law firms and corporate clients with the calculation of damages, econometric model building, forecasting, market studies, profitability analysis, valuation and product pricing studies.  As part of his practice, Richard also provides economic and strategy consulting on pricing and contracting issues.

Richard focuses on economic consulting and quantifying damages in all forms of intellectual property disputes including patents, trademarks, copyright, trade dress and trade secrets, as well as other complex commercial disputes. Representative intellectual property assignments include quantifying economic damages in the form of lost profits, reasonable royalties, price erosion and convoyed sales. He has also evaluated intellectual property in non-dispute contexts such as licensing and transactions. 

[back to top]

Sian Godwin, Licensing Director, GE Healthcare
Sian GodwinSian is currently Director of Licensing for GE Healthcare's Life Sciences Division based in Piscataway, New Jersey managing both in-licensing and out-licensing activities and supporting M&A transactions . Sian joined GE through its acquisition of Amersham International in 2004, shortly after the acquisition she relocated from South Wales in the UK to New Jersey to take up a dedicated licensing role. Prior to that she held various positions in Marketing, Product Management, Project Management and Manufacturing . Sian has a B.Sc (Hons) in Applied Biological Sciences and is a CLP.

[back to top]

Klaus Göken, Patent Attorney, Partner, Eisenführ Speiser
Klaus GökenBorn in 1961 in Thulsfelde, Germany, married, three sons.

Studied Electrical Engineering at the Technical Universities of Hanover and Munich, specializing in telecommunications engineering, electroacoustics, electronics, television engineering, control systems and digital message processing. Research and development work in the semiconductor field at IBM and Siemens.

Legal training from 1990 to 1994 in the Patents/Trademarks/Licensing Dept. of Thomson Consumer Electronics/Telefunken Fernseh und Rundfunk GmbH in Hanover, London, Paris and Princeton/MA, at the German Patent and Trademark Office and the German Patent Court.

European Patent Attorney since 1993 and German Patent Attorney since 1994, at Eisenfuhr Speiser since 1994.

North German Director of University of Strasbourg CEIPI training in European patent law.

[back to top]

Susan Goldsmith, Partner, SorinRand LLP
Susan GoldsmithSusan Okin Goldsmith is a partner of SorinRand LLP. Her practice focuses on intellectual property, including global registration and enforcement strategy, domestic and foreign trademark clearance and registration, infringement matters, and intellectual property licensing. Susan handles a wide variety of matters involving computer hardware and software vendors and purchasers, software and other technology licensing, e-commerce and internet use and abuse, and issues involving international trade. Susan also has an extensive track record with respect to corporate and commercial business transactions, joint ventures and start-ups, including complex mergers and acquisitions and venture capital financing, handling substantial licensing and other intellectual property and technology issues.  She has also handled numerous domestic and foreign trademark opposition, cancellation and invalidity actions.

Susan has been 2012-13 co-chair of the Software Licensing Subcommittee of LES US-Canada.  She is a Certified Licensing Professional.  She is featured in the World Trademark Review’s WRT 1000 for 2012 and 2013 - The World’s Leading Trademark Professionals, and has also been selected to New Jersey Super Lawyers lists in these years and others.

[back to top]

Anthony Green, Ph.D., Vice President, Technology Commercialization Group - Life Sciences, Ben Franklin Director - The Nanotechnology Institute and Energy Commercialization Institute, Ben Fraklin Technology Partners - SEP
Anthony GreenAnthony P. Green, Ph.D., is Vice President, Technology Commercialization Group: Life Sciences for Ben Franklin Technology Partners of Southeastern PA (BFTP/SEP) and Ben Franklin Director of The Nanotechnology Institute™ (NTI) and Energy Commercialization Institute. He is also a Visiting Research Professor, School of Biomedical Engineering, Drexel University.

At BFTP/SEP, Dr. Green is focused on Ben Franklin's larger and region-wide technology partnerships and major initiatives, including the NTI and the Energy Commercialization Institute (ECI). He is also focused on new and evolving life sciences initiatives, university/industry partnerships in advanced textiles and water and the development and implementation new commercialization models. He is Chair of the Innovation Partnership Program, and a member of the Board of Visitors of the University of the Sciences Misher College of Arts and Sciences and the PA Life Science Leadership Advisory Council. Dr. Green has over 30 years experience in the biotechnology industry focusing on diagnostics and gene transfer technologies. In addition to his work with BectonDickinson and Migliara/Kaplan Associates, Dr. Green track record includes research, development and commercialization of cutting-edge technologies primarily through small, emerging companies, including Centocor and Puresyn. Dr. Green earned his Bachelor of Science degree in Immunology, with Honors, from Brown University, in Providence, Rhode Island and his Ph.D. from Temple University School of Medicine, in Microbiology and Immunology.

[back to top]

Mike Gross, Senior Licensing Manager, Kimberly-Clark
Mike GrossMike Gross is a Senior Licensing Manager at Kimberly-Clark Corporation. Kimberly-Clark and its well-known global brands, such as Kleenex, Scott, Huggies, Pull-Ups, Kotex and Depend, are an indispensable part of life for people in more than 175 countries. In his position in Global Licensing in the Corporate Research & Engineering organization, Mike is responsible for monetizing K-C patents and know-how. Mike knows Kimberly-Clark's patent and technology portfolio very well after working at K-C for 25 years in Design Engineering, Manufacturing Engineering, Project Engineering, B2B Marketing and Product Management roles. He has extensive experience in nonwoven fabrics engineering and marketing. He has managed business teams with product development, marketing, sales and P&L responsibility. Mike also has experience in new business development, including launching a consumer product. He has three granted U.S. Patents. Mike holds a Bachelor of Mechanical Engineering degree from Georgia Tech and an MBA degree from Georgia State University.

[back to top]

Gary Haag, PhD, CLP, Contracts Consultant, ConocoPhillips
Gary HaagGary Haag is a Contracts Consultant in the LNG Technology and Licensing Group at ConocoPhillips Company. Prior to this assignment in 2008, he was a Senior Counsel in the Intellectual Property group in ConocoPhillips Legal department, having joined Phillips Petroleum Company (now ConocoPhillips) in 1991 and during which time his responsibilities included patent prep and prosecution in support of ConocoPhillips upstream, refining and natural gas liquefaction technologies, transactional support in relation to such technologies, most notably the out-licensing of ConocoPhillips technologies, and litigation support. He now exclusively focuses his efforts on the out-licensing of ConocoPhillips proprietary technology for natural gas liquefaction, that being the Optimized Cascade Process®. Mr Haag has BS, MS, and PhD degrees in chemical engineering. Prior to joining ConocoPhillips, he worked as a research engineer at Amoco Production Company for 9 years focusing on EOR technologies and at Oak Ridge National Laboratory for 6 years focusing on off-gas clean-up at nuclear facilities. He is licensed to practice law in Oklahoma and Texas and before the US PTO, a registered professional engineer in Tennessee and Oklahoma, and a Certified Licensing Professional.

[back to top]

R. Mark Halligan, Partner, Nixon Peabody
R. Mark HalliganR. Mark Halligan is an accomplished trial lawyer who focuses his practice on intellectual property litigation and complex commercial litigation. He has represented individuals and corporations as plaintiffs and defendants, trying cases involving patent, trademark, and copyright issues. Mark is as a sought-after practitioner in trade secrets law, and has successfully tried cases regarding the misappropriation, protection and enforcement of trade secrets. He is frequently retained by corporate entities to counsel and conduct audits on trade secret issues.

Mark is a prolific lecturer on trade secrets and intellectual property issues, and serves on the Adjunct Faculty of The John Marshall Law School in Chicago, where he teaches trade secrets law. Mark has been ranked professionally in numerous international publications as a leading practitioner in intellectual property and trade secrets law. He holds a J.D. from Northwestern University and a B.A. summa cum laude from the University of Cincinnati.

[back to top]

John Hamann, Principal, Hamilton, Brook, Smith, Reynolds
John HamannJohn Hamann's practice focuses on patent litigation in the federal district courts and the United States International Trade Commission, primarily in the electrical and computer arts. John has extensive experience litigating patents spanning a wide range of technologies, including semiconductor design and manufacture, memory devices, image sensors, networking hardware, Power over Ethernet devices, VoIP phones, circuit design, telecommunication hardware, wireless devices, software, and Internet-related technologies.

With over a ten year focus on complex patent litigation, John has extensive experience in all stages of patent disputes, from pre-litigation counseling through trial.  Prior to practicing law, John was the Manager of Engineering Systems at a leading radio frequency consulting firm and a Communications Engineer for a certified frequency coordinator of the Federal Communications Commission.  Prior to joining Hamilton Brook Smith Reynolds, John was a partner at Howrey LLP and Hogan Lovells US LLP in San Francisco, California.

[back to top]

Robert Heath, Senior Vice President, Corporate Development, RPX Corporation
Robert HeathRobert Heath is Senior Vice President of Corporate Development at RPX Corporation, the leading provider of patent risk management solutions. Mr. Heath focuses on RPX's corporate strategy, new business initiatives, and advises RPX clients on syndicated acquisitions of patent portfolios.

Prior to RPX, Mr. Heath served as Head of Strategy and Global M&A for Technicolor, a leading supplier of technology and services to media companies, where he oversaw an acquisition and divestiture program that refocused the company from consumer electronics to services and technology licensing.  Prior to Technicolor, Mr. Heath served as Chief Operating Officer and Chief Financial Officer at iBahn, an Internet service provider to the hospitality industry.

Mr. Heath has extensive experience as an investment banker, focused on technology and growth companies at Kidder Peabody, SG Warburg and Robertson Stephens.  During his investment banking career, he worked in corporate finance and mergers and acquisitions, completing deals with more than $10 billion in transaction value.

Mr. Heath began his career as a litigation technology consultant with Price Waterhouse, where he designed computerized systems to support document discovery and expert witness testimony in multi-plaintiff litigation.

Mr. Heath received his MBA from the University of Chicago Booth School of Business and his BA from Harvard College.

[back to top]

Chris Hoecke, CEO, Mallard Research
Chris HoeckeChristopher Hoecke is the CEO of Mallard Research, a firm blending extensive experience in the finance and biotechnology industries to develop robust valuation models for biotech products and the companies that develop them. Mr. Hoecke has spent years assessing the healthcare investment landscape with an emphasis on companies developing drugs, diagnostics, and medical devices. An in vitro-diagnostics scientist, Mr. Hoecke has over a decade of experience in various aspects of product development and manufacturing technical-support in a GMP environment. He has participated in the conduct of clinical trials and validations of assays in both clinical and research settings.

Prior to his work with Mallard, Mr. Hoecke worked as a research and senior scientist, and later as a marketing support specialist at American Diagnostica of Sekisui Medical Group.  Prior to that, Mr. Hoecke was a research scientist at Biomerieux, where he was involved in product development, as well as in the management of process validation and manufacturing support efforts, including an intensive site-wide FDA compliance initiative. 

[back to top]

Krista Holt, President and CEO, GreatBridge Consulting, Inc.
Krista HoltKrista F. Holt, CLP, CVA, is the President and CEO of GreatBridge. She has provided services, including expert testimony, surveys, valuation, strategic counseling, and consulting in over one hundred and seventy-five intellectual property cases in various industries.  Ms. Holt has testified on issues informing economic damages, lost profits, reasonable royalties, price erosion, competition, valuation of intellectual property, marketing, and management practices.

Ms. Holt previously served as Vice President at The Kenrich Group, a national business and litigation consulting firm, where she founded and managed the Intellectual Property Practice.  Prior to that, Ms. Holt founded and led the Washington, D.C. Expert Testimony Practice and National Survey Practice as a Managing Director for Ocean Tomo, a firm providing financial products and services related to intellectual property.

Ms. Holt is the Chair of the LES Valuation and Taxation Committee.  She has lectured on a variety of intellectual property topics for the American Bar Association, Licensing and Executives Society, DRI, Harvard Law, George Washington Law School and various other organization and universities. Ms. Holt holds an MBA from the University of Louisville and a BA from Wake Forest University.

[back to top]

Mark Horsburgh, Principal, Fisher Adams Kelly
Mark HorsburghMark has more than 20 years of patent and trade mark experience specialising in physical chemistry, nanotechnology, applied laser technology, fibre optics, information technology, electronics, defence technology, medical devices and general engineering.

Mark's experience includes Post-Doctoral and professional work at the University of New South Wales and the University of Queensland. Mark spent two years as a Research Scientist with the Defence Science and Technology Organisation before specialising in Intellectual Property protection and bringing that capability to Fisher and Kelly (now Fisher Adams Kelly) in 1993.

Mark is Immediate Past President of LESANZ and is co-chair on LESI Meetings Committee. Mark sits on the Professional Dtandards Board for patent and trademark attorneys in Australia and is a graduate of the Australian Institute of Company Directors.

[back to top]

Kevin Jakel, CEO, Unified Patents
Kevin JakelKevin Jakel is the CEO and founder of Unified Patents Inc., a defensive venture designed to deter NPE activity from strategic technologies.  Prior to Unified, Kevin served as Intuit's Head of IP Litigation.  Kevin was a patent litigator with Kaye Scholer LLP and Howrey LLP and before that he began his career in IP as a patent examiner at the U.S. Patent & Trademark Office.  Kevin has a JD from George Washington University Law School and a BS in mechanical engineering from UCLA.


[back to top]

Mary Juetten, Founder & CEO, Traklight
Mary has over twenty-five years of leadership experience in both the public and private sectors. She is a self-described recovering accountant, holding both a CA and CPA, and a Bachelor of Commerce from McGill University and a JD from Arizona State. Her prior work experience includes financial auditing with Richter, Usher, & Vineberg, consulting with Price Waterhouse, and executive positions with Vancouver Community College, AMEC Training & Development, and Chief Operating Officer with a local online startup, youchange Inc.

In 2010, while enduring law school, Mary founded traklight.com, a site that provides inventors, creators, and small businesses with the tools to identify and protect their intellectual property (IP).  Mary also consults and mentors start-ups in the areas of planning, business models, and IP identification.

In addition to her volunteer work, Mary is an active leader and member for local groups and organizations including 85Broads (Co-President), Arizona Tech Council’s Startup & Entrepreneurship Committee, Arizona Small Business Association, Startup Arizona, TiE, ASU Women in Philanthropy, and national crowdfunding organizations CFPA and CfiRA.

A native of Canada, Mary now lives in Phoenix, AZ with her husband and teenagers.

[back to top]

Tariq Kassum, Vice President, Business Development and Strategy, Millennium: The Takeda Oncology Company
Dr. Tariq Kassum is Vice President, Business Development and Strategy, for Millennium: The Takeda Oncology Company, with responsibility for transactions and collaborations, alliance management with key partners, and strategic planning. In his previous role he led Takeda's U.S. corporate development efforts where he managed the acquisition of URL Pharmaceuticals, including the divestiture of URL's generic pharmaceuticals business, and the acquisition of Inviragen. Tariq joined Takeda from Seneca Capital, a multistrategy hedge fund, where he was a senior analyst covering healthcare equities. He began his career as an investment banker with CIBC World Markets serving clients in the biotechnology and specialty pharmaceuticals industries. Tariq received his medical degree from the University of Toronto and an A.B. from Cornell University.

[back to top]

Efrat Kasznik, President, Foresight Valuation Group
Efrat KasznikMs. Kasznik is an intellectual property (IP) and valuation expert, with close to 20 years of consulting experience, focusing on assisting clients with the management, commercialization and monetization of their IP and technologies. She is a Lecturer on IP Management at the Stanford Graduate School of Business. Ms. Kasznik is the founder and president of Foresight Valuation Group, a Silicon-Valley based intellectual property, valuation and start-up advisory firm. She is a frequent speaker and author on IP valuation and strategy issues. Ms. Kasznik is Chair of the Nanotechnology Committee of the Licensing Executives Society (LES), a global organization of IP professionals, as well as a member of the leadership committee of the LES High Tech Sector.

Ms. Kasznik specializes in analyzing and valuing IP portfolios for a range of purposes, including: mergers & acquisitions, financial reporting, technology commercialization decisions, tax compliance, transfer pricing, litigation damages and business liquidations. She has worked with corporate clients that range in size from Fortune 100 to start-ups, law firms, universities, research institutions, inventors, IP brokers and patent funds. Prior to founding Foresight, Ms. Kasznik was Senior Vice President with ICMG, a consulting firm specializing in intellectual capital management, where she led the IP valuation and litigation practice for close to a decade. She moved on to become a Director with LECG, a global litigation-consulting firm, where she created a new practice area focused on Intellectual Asset Management.

Throughout her career, Ms. Kasznik also served as a co-founder and advisor to several Silicon Valley start ups, including serving as Chief Financial Officer at a telecom start-up, and most recently as a co-founder of an energy efficiency start up, where she is also designated as co-inventor on patents related to analyzing residential energy usage. She serves as a mentor to several startup incubators in the US and in Europe, and routinely advises startups on topics related to business strategy, financial modeling and IP portfolio management. Ms. Kasznik holds an MBA from the University of California, Berkeley.

[back to top]

Paul C. Kerkhoven, Director Government Relations, NGVAmerica
Paul C. Kerkhoven is the Director, Government Relations for NGVAmerica.  Paul has over 25 years experience in government relations, involving energy, environment and transportation policy.  He has testified before Congress, and in the past served as Legislative Assistant to U. S. Senator William V. Roth, Jr. (R-DE), and as the Director of Environmental Affairs for the American Highway Users Alliance.  He received his Master in Public Administration in energy and environmental policy from the University of Delaware and holds a B.Sc. in Biology from the University of Waterloo, in Ontario, Canada.  He is fluent in Dutch and French and is an accomplished gold and silversmith. 

[back to top]

William Kerr, Director, Berkley Research Group
William KerrWilliam Kerr is an expert in the economics of intellectual property and competitiveness. He has produced several books and articles on these subjects, including a leading treatise on the economics of intellectual property damages (with co-author Dick Troxel), now in its sixth edition.

In more than 30 years as a professional economist, Dr. Kerr has taught economics and statistics and advised government and private clients on issues ranging from tax policy to economic development and on mergers and acquisition matters, as well as the development of international trade and licensing programs. He has testified as an expert in litigation related to intellectual property, antitrust issues, commercial disputes, international trade, and employment and discrimination matters. 

[back to top]

Ron Laurie, Managing Director, Syndicated Patent Acquisitions Corp.
Ron LaurieRon Laurie has worked in Silicon Valley since before it had that name, initially as a software and systems engineer, and then as an IP lawyer and patent strategist. In 2004, he founded Inflexion Point Strategy, LLC, the first IP investment bank, which provides patent brokerage and IP-driven M&A advisory services. Ron is the co-founder and President of Syndicated Patent Acquisitions Corporation ("SynPat"), which acquires high-impact patent portfolios using a highly innovative licensee-syndication model. Ron was a founding partner of Skadden Arps' Silicon Valley office, where he founded and chaired the firm's IP Strategy and Transactions practice group for six years. He was also a founding partner of the Silicon Valley offices of Weil, Gotshal and Irell & Manella. Ron advised clients in the semiconductor, computer, software, communications, media and financial services industries on IP strategy -- a subject he has taught at Stanford and Boalt (UC Berkeley) law schools. At Skadden, Ron led IP teams in some of the largest high-tech and life sciences M&A and joint venture deals ever done, worth over $50 billion in the aggregate.

[back to top]

Alan Leeds, Partner, Morgan, Lewis and Bockius
Alan LeedsAlan Leeds is a partner in the business and finance group at the law firm of Morgan, Lewis and Bockius. Alan's practice focuses on advising and representing companies and investors in a variety of transactions, including mergers and acquisitions, joint ventures and strategic partnerships, and venture capital financings. Alan has extensive transactional experience representing and advising life sciences companies that range from early-stage biotechnology startups to global pharmaceutical companies, including in connection with strategic alliances and other complex collaborations, licensing transactions, supply and distribution arrangements, and product acquisitions and divestitures. Alan received his law degree from Harvard Law School and his undergraduate degree from the University of Pennsylvania, Wharton School of Business.

[back to top]

Russell Levine, Partner, Kirkland & Ellis LLP
Russell LevineMr. Levine is a Partner at Kirkland & Ellis LLP where he has spent his entire 25+ year career.  He focuses his trial, appellate and alternative dispute resolution practice on patent infringement matters and disputes involving and related to technology transfer and patent license agreements.  His trial practice includes jury trials, arbitrations and Section 337 proceedings before the U.S. International Trade Commission.  His appellate practice concentrates on appeals in the Court of Appeals for the Federal Circuit.  His technology transfer and licensing practice includes structuring and negotiating both licensing-in and licensing-out transactions.

Mr. Levine has received numerous accolades for his IP practice.  His strategy of seeking and obtaining a Writ of Mandamus earned "stand-out" recognition in The Financial Times, U.S. Innovative Lawyers 2011.  Mr. Levine also won the International Law Office 2012 Client Choice Award in Litigation for the U.S.  The clients ILO interviewed had this to say about him:

  • "Russell has that unique ability to provide legal advice in a manner that is understandable, practical and useful for our business."
  • "Mr. Levine is constantly reachable and willing to take on tough assignments. He is up to date with the law and able to provide solutions to numerous problems without excessive research,"
  • "Russell always maintains a keen focus on the client's objectives and need for a business solution to litigation," and
  • "Russell stands out as good communicator. His manner instills confidence when called upon to present matters to the management team."

Mr. Levine is named in the 2012 edition of IAM Patent 1000: The World's Leading Patent Practitioners and IAM Strategy 300: The World's Leading IP Strategists.  These and previous IAM publications state that:

  • "He is fantastic and has a knack for breaking down complex subjects to their essentials without getting caught in the weeds.  He really knows his audience and how to get points across effectively."
  • Russell "brings a great sense for clients' IP objectives to the table,"
  • he is "well known for the depth of his licensing expertise," and
  • "for the most important cases, he is one of the leading figures in Chicago and nationally."

Mr. Levine is listed in the 2012 edition of Legal 500 US which describes him as "a first-class professional that presents himself and the firm in a down-to-earth manner that always keeps the best interests of the client first."  In its 2011 edition, Legal 500 US stated that "Russell comes highly recommended: ‘his strength is in understanding the issues in a business context and seeking creative ways to end litigation.'"  In its 2010 edition, Legal 500 US referred to him as an "outstanding strategist."

Mr. Levine has been included in Chambers USA each year since 2008 with comments describing him as being "an awe-inspiringly good litigator," "an excellent patent litigator," and "very bright and effective," and praising him "for delivering pragmatic and well-reasoned legal advice in an understandable, business-friendly way."  He has been named each year since 2004 by the Leading Lawyers Network to be one of the Top Lawyers in Illinois in Intellectual  Property.

Mr. Levine is active in bar associations, industry organizations, and his community.  He is the President-Elect of LES (USA & Canada).  He also is vice-chair of Division V (Professional Issues) within the IP Section of the American Bar Association.  He is on the American Heart Association's Chicago Board of Directors.  He is the immediate Past-Chair of the President's Council at Chicago's Museum of Science and Industry.  He also is Chair of the By-Laws Committee of the Midwest Section of the United States Tennis Association.

Mr. Levine is an author and frequent speaker on Intellectual Property issues.  For example, he is co-editor (with A. Liberman of Australia and P. Chrocziel of Germany) of "International Licensing and Technology Transfer:  Practice and the Law."  This publication started shipping in 2008 and quickly obtained a global audience with copies sold in more than 30 countries across six continents.  His "Top 10" workshop at the LES Annual Meeting consistently is standing room only; he has spoken at numerous LES local chapter meetings and LESI National Society meetings; and he has been an instructor in several LES educational courses.  Since 1988, he also has taught a course for the Society of Automotive Engineers entitled "Patent Law for Engineers."

Mr. Levine holds a B.S. in Interdisciplinary Engineering and a B.S. in Economics, both degrees from the University of Michigan.  He received his law degree from the University of Chicago.  Mr. Levine is on the World Intellectual Property Organization's List of Mediators and Arbitrators, he is a Certified Licensing Professional (CLP)*, and he is registered to practice before the United States Patent and Trademark Office, the United States Supreme Court, and numerous Circuit Court of Appeals and District Courts.

* The Supreme Court of Illinois does not recognize certifications of specialties in the practice of law and the CLPTM certification is not a requirement to practice law in Illinois.

[back to top]

Traci Libby, Director, Corporate Development; Global Head of In-Licensing, Life Technologies Corporation
Traci LibbyTraci Libby, CLP, currently serves as Director of Corporate Development, Global Head of In-licensing at Life Technologies. In this capacity, she has global responsibility for external technology sourcing and acquisition, in-licensing and other non-M&A partnering transactions, as well as oversight of license compliance. Traci originally joined Life Technologies through Invitrogen and has been at the company for the past thirteen years. Prior to her tenure at Life Technologies, Traci served as the head of new product development and as a senior product marketing manager at Chemicon International (now EMD), manager of global techical support at Calbiochem Corporation (also now EMD), and laboratory director at a small contract viral and interferon bioassay services provider. Traci obtained her bachelor's degree in biochemistry and cell biology at the University of California, San Diego, and did her graduate studies in molecular and cell biology at San Diego State University.

[back to top]

Jiaqing "Jack" Lu, PhD, CFA, Chief Economist and Senior Director for IP Market Advisory Practice (IPMAP), Applied Economics Consulting Group, Inc.
Jack LuJiaqing "Jack" Lu, PhD, CFA, Chief Economist and Senior Director for IP Market Advisory Practice (IPMAP), Applied Economics Consulting Group, Inc. Dr. Lu specializes in business valuation, IP valuation, competition assessment, and market analysis, and has substantial experience in economic & financial analysis for IP management and monetization. He leads the firm's IPMAP that develops and executes IP investment and divestiture strategies for clients in technology industries. An IP economist and financial analyst with engineering background, Jack's researches in IP, patent market, financial markets and other economic issues have been published by the Council on Foreign Relations, Cambridge University Press, Business Economics, Les Nouvelles, and Licensing Economics Review. He was an expert speaker at IP forums organized by Duke Law School, LES, and other entities, and was interviewed and profiled by CFA Magazine and Licensing Economics Review. Jack's recent research can be found at his SSRN author page at ssrn.com/author=230071.

[back to top]

Gene Lucadamo, Center for Materials and Nanotechnology - Industrial Liaison Officer, Lehigh University
Gene LucadamoGene Lucadamo is the Industrial Liaison Officer for the Center for Advanced Materials and Nanotechnology (CAMN) at Lehigh University, which coordinates activity in nanotechnology and materials. He manages the Industrial Liaison Program (ILP) for R&D collaborations with businesses and government, and the 200 member Lehigh Nanotech Network (LNN).

Mr. Lucadamo holds B.S. and M.S. degrees from Lehigh in Chemical Engineering. In a prior career with Air Products, he held positions in technology development and process and project management in energy generation and conversion, petrochemical processes, and industrial gases.

[back to top]

Richard M. Ludwin, Associate General Counsel, Intellectual Property Law, IBM
Richard LudwinRichard M. Ludwin is Associate General Counsel, Intellectual Property Law for International Business Machines Corporation. Based in Armonk, New York. Mr. Ludwin directs IBM's worldwide intellectual property licensing attorney staff and provides executive guidance for IBM's Intellectual Property Law departments in Systems and Technology Group, Global Services and Sales & Distribution. Since joining IBM in 1988 Mr. Ludwin has served as an attorney in Washington DC, Poughkeepsie and IBM Research. He has also served as an IBM Patent Portfolio Manager, IP Counsel for IBM's Almaden Research center, Counsel for the IBM Corporate Intellectual Property Department and senior IP Counsel for the IBM Research Division. He is registered to practice before the United States Patent & Trademark Office and admitted to the bars of New York, New Jersey, Florida and the District of Columbia.

[back to top]

Kenneth Lustig, Vice President, Global Licensing, Intellectual Ventures
Ken LustigKenneth Lustig joined Intellectual Ventures (IV) in 2011, and is currently Vice President Global licensing, overseeing Strategic Portfolio Monetization. Mr. Lustig leads the team responsible for the development, management and monetization of a range of IV's largest strategic IP portfolios.  He is a member of the company's Global Licensing leadership team, which is responsible for revenue generation across all company funds.  Mr. Lustig also oversaw IV's Strategic Acquisitions Group and the Global Customer Engagement team.

Prior to joining IV, Mr. Lustig spent more than 11 years at Microsoft, where he served most recently as the Managing Director of IP Investments and Acquisitions. He led the Content Guard IP joint venture, as well as some of Microsoft's largest IP investments, licensing deals and patent litigation settlements.  Mr. Lustig closed over $3 billion of transactions at Microsoft, including creating and overseeing a diversified IP investment portfolio and managing the Company's inbound IP transactions team.  He also spent several years leading part of Microsoft's Corporate Development and Strategy Group and was a member of the Company's Business Development leadership team. Preceding Microsoft, Mr. Lustig spent nine years as a global investment banker.

Mr. Lustig received his bachelor's degree in political science from the University of California, Los Angeles, and his master of business administration in finance from New York University.

[back to top] 

Timothy Lynch, Chief IP Officer, Kodak
Timothy LynchTimothy M. Lynch is Chief Intellectual Property Officer, Deputy General Counsel and Vice President of Eastman Kodak Company.

Mr. Lynch joined Kodak in 1997 as a member of the Corporate and Regulatory Legal Staff, supporting merger, acquisition, and divestiture transactions.  He has held increasingly responsible positions in the Intellectual Property area since 2004.  Prior to joining Kodak, Mr. Lynch held positions with GE Capital and Nixon Hargrave Devans & Doyle (now Nixon Peabody).

Mr. Lynch holds a B.A. in communications and political science from St. John Fisher College and a J.D. from the University of Dayton School of Law.  He is a member of the New York Bar.

[back to top]

Michele Marcolongo, Ph.D., P.E., Sr. Associate Vice Provost for translational Research, Drexel University
Michele MarcolongoDr. Michele Marcolongo serves as Senior Associate Vice Provost for Translational Research at Drexel University and is a Professor of Materials Science and Engineering.  For Drexel University, Dr. Marcolongo works to help translate research discoveries from the laboratory toward commercialization.  She serves on the Operations Boards of the Nanotechnology Institute and the Energy Commercialization Institute.  Dr. Marcolongo's field of research is biomaterials or materials that can be implanted into the body to replace diseased or damaged tissues. Specifically, she works on injectable biomaterials to replace and augment degenerated intervertebral discs, which are a primary cause of lower back pain.  Dr. Marcolongo has co-founded two companies with technologies that treat lower back pain due to intervertebral disc degeneration:  the first, Gelifex, was sold to a major orthopaedics manufacturer and currently under commercialization and the second, SanoSpine was recently incorporated to commercialize a platform technology of biomimetic proteoglycans.  Dr. Marcolongo received her doctorate in Biomedical Engineering from the University of Pennsylvania, and is a graduate of the University of Delaware, Department of Mechanical Engineering (1986).

[back to top]

Richard M. Marsh, Sr.,  Executive Vice President, General Counsel and Secretary, Myriad
Richard MarshRichard Marsh joined Myriad in November 2002. Prior to joining Myriad, Mr. Marsh served in various positions at Iomega Corporation including Acting General Counsel, Director of IP and Director of Commercial Legal Affairs. Prior to joining Myriad and Iomega, Richard was a partner with the Salt Lake City law firm of Parsons Behle & Latimer.  Richard received a Masters of Laws degree in Taxation from Georgetown University Law Center; a law degree from Thomas M. Cooley Law School, graduating magna cum laude; and a Bachelor of Science degree in Accounting from Brigham Young University; and was formerly a Certified Public Accountant. 

[back to top]

John McCauley, SVP, Strategic Alliances, Screenvision
John McCauleyAs SVP of Strategic Alliances at Screenvision, John McCauley oversees all of the company's partnerships with content producers and creative service providers.

Prior to joining Screenvision, McCauley connected brands and media companies with new technology media, content and other emerging opportunities through his own agency, Flying Tiger Enterprises. He also led branding, media, digital programming and online marketing initiatives as CMO of CBS College Sports Network, and worked on film and TV properties as EVP of Global Marketing Partnerships for The Weinstein Company.

McCauley holds a bachelor's degree in Accounting from Kings College in Wilkes-Barre, PA, and an MBA in Marketing from Vanderbilt University's Owen School.

[back to top]

Thomas McGahren, Senior Managing Director, Investment Banking at Griffin Securities
Thomas McGahrenTom McGahren is a Senior Managing Director and investment banker at Griffin Securities in Manhattan where he advises and represents biotechnology and other life science companies in strategic, M&A and financial matters.  Prior to Griffin, Tom was a senior biotechnology analyst at Merrill Lynch where Forbes ranked him the #1 Drugs Analyst in 2008. He began his career on Wall Street as as a biotechnology analyst at Banc of America Securities in 2002. Prior to Wall Street, Tom was a litigator at the international law firm of Kaye Scholer from 1993 to 2001 representing pharmaceutical, biotechnology and medtech companies, particularly in intellectual property, FDA, and corporate matters. Tom holds an M.D. from the University of Virginia School of Medicine, a J.D. from the University of Texas School of Law, and a B.A. from Colgate University.

[back to top]

Thomas Meagher, Managing Partner, Meagher Emanuel Laks Goldberg & Liao, LLP
Thomas MeagherTom Meagher focuses his practice on patent litigation, patent licensing, and patent prosecution management, and has substantial experience working with universities and with electronic, computer, telecommunications, and healthcare technology companies.

He has assisted General Electric Company, Princeton University, France Brevets, and others in patent licensing, and has managed extensive patent prosecution work for research institutions, including Princeton University and Massachusetts Institute of Technology. He has handled patent litigation for Boston Scientific, Hewlett-Packard, Hitachi, Intel, and Microsoft, among many others.

Tom's career spans more than 30 years, including serving in the patent departments of RCA Corporation and ITT Corporation, and nearly two decades with Kenyon & Kenyon.

Tom has a B.S., Electrical Engineering, from Carnegie Mellon University, and a J.D. from Catholic University of America, Columbus School of Law. Tom is admitted to practice law in NY, NJ, and PA. He is also registered to practice before the United States Patent and Trademark Office.

[back to top]

Luis Mejia, Senior Associate, Stanford University
Luis MejiaMr. Mejia is a Senior Associate in the Office of Technology Licensing at Stanford University. He manages a portfolio of over 300 technologies ranging from biotech to cleantech, including Stanford’s two biggest patented cases. In his 25 years at Stanford, he has managed three major patent litigations (including two cases argued before the US Supreme Court), negotiated over 250 licenses, and evaluated over 700 inventions, including the PageRank Algorithm which was the instrumental IP that led to the creation of Google. Mr. Mejia has been an advisor to Silicon Valley start-ups, Los Alamos National Laboratory, Monterey Bay Aquarium Research Institute and is a Board Member of the Stanford University OTL, LLC. Mr. Mejia received his engineering degree in Mechanical Engineering from Arizona State University and is a Certified Licensing Professional. Prior to joining Stanford he worked on solar energy systems and energy management at Honeywell and Pacific Gas & Electric. Mr. Mejia is a Fellow of the Disruptor Foundation.

[back to top]

Gayle M. Mills, M.B.A. Chief Business Officer, Symphogen
Gayle MillsGayle is currently the Chief Business Officer for Symphogen A/S headquartered in Copenhagen, Denmark.   Recent accomplishments include the world-wide out-license of Symphogen's lead oncology program to Merck KGaA. As CBO, she is responsible for Symphogen's business development  and intellectual property activities .

Prior to Symphogen, Ms. Mills held the position of SVP at ROXRO PHARMA, where she was oversaw business operations leading to the successful FDA approval of ROXRO's novel analgesic, SPRIX® and the subsequent acquisition of the company by Luitpold Pharmaceuticals, a subsidiary of Daiichi Sankyo. Prior to that, Ms. Mills was SVP of Business Development at Abgenix, Inc. a successful antibody discovery and development company acquired by Amgen. Ms. Mills' accomplishments include consummation of a wide range of significant licensing, co-development and corporate acquisition transactions.

[back to top]

Polly Murphy, Vice President, Specialty Care Business Unit BD, Pfizer
Polly MurphyPolly Murphy, Vice President, Specialty Care Business Unit BD, is responsible for the technical and commercial evaluations and completing the transactions for opportunities that complement Pfizer's specialty care and vaccine disease areas in developed markets. Before this role, she led Pfizer's Worldwide R&D Business Development team, responsible for early stage licensing through POC in man.

Prior to Pfizer, Polly held positions in Licensing, IP Management, and Operations at The Scripps Research Institute and The Salk Institute for Biological Studies. Previously she was in Business Development at Aurora Biosciences, Dupont Pharmaceuticals and Nabi Biopharmceuticals. She headed the U.S. marketing team that launched DuPont Pharma's HIV drug, Sustiva. She began her career at Hoffman-LaRoche as a post-doc in the experimental pathology group followed by positions in sales and marketing.

In her spare time she enjoys surfing (although not often now that she lives in PA), golf, and spending time with her husband and two sons.

[back to top]

Charles Murray, Global Managing Director, DuPont
Charles MurrayChip Murray leads the Intellectual Assets & Licensing business of DuPont, a position he assumed in April 2002. The Global Managing Director of Intellectual Assets & Licensing has profit and loss responsibility for all out-licensing activities within the corporation. Intellectual Assets & Licensing is chartered with leveraging and extracting maximum value for DuPont technology, intellectual property and knowledge. Prior to his current position, he held management positions in DuPont's Polyester Enterprise, including most recently, assignments as Global Technology Director and Director of Strategic Planning for Dacron®. His over 35-year career with DuPont has included assignments at many DuPont locations, and a variety of disciplines including Engineering, Marketing & Sales, Manufacturing and Technical leadership. While Director of Strategic Planning for Dacron®, Chip negotiated strategic alliances or JV's with Unifi in USA, Akra Group in Mexico, Suzhou in PR China and Sabanci in Europe. In addition to their role in licensing DuPont technologies, IA&L assists many DuPont businesses to form strategic supply alliances and business relationships with our licensees. Chip graduated with a BS in Engineering from Virginia Polytechnic Institute. Prior to DuPont, Chip worked for Shell Oil as a power systems engineer at the Norco, Louisiana refinery and chemical plant. Chip currently resides in West Chester, Pennsylvania with his wife Laurie and two children, Alex (24), and Malorie (18). Chip is an avid golfer who also enjoys tennis, basketball and traveling with his family.

[back to top]

Alan Naidoff, Director, Licensing & Research Contracts Management, Merck Sharp & Dohme
Alan NaidoffAlan Naidoff is a Director of Licensing and Research Contracts Management in Merck Sharp & Dohme Corporation's Department of External Scientific Affairs. Dr. Naidoff earned a B.S. in Biology from Cook College - Rutgers University, a D.M.D. from Temple University School of Dentistry, and a J..D. from Widener University School of Law. In addition, Dr. Naidoff attended a two year General Practice Residency focusing on general dental practice, internal medicine, oral and maxillofacial surgery and pathology at the Medical College of Pennsylvania. For the past fifteen years at Merck, Dr. Naidoff has been responsible for the negotiation and execution of numerous research agreements with both academia and industry.

[back to top]

Stephen G. Nappi, Associate Vice Provost for Technology Development and Commercialization, Temple University
Stephen NappiStephen Nappi has over 12 years of experience in the technology transfer business and currently serves as Director of Technology Development and Commercialization at Temple University.

Since joining Temple in 2008, Mr. Nappi continues to lead the commercialization enterprise through significant growth, including an increase in revenue from $340K in 2008 to $11.5M in 2013. In addition, new inventions doubled over the same period with seven companies formed in the past 2 years, the establishment of incubation space, a proof-of-concept funding program, and a new business development arm. Prior to joining Temple, Mr. Nappi advanced through all levels of technology transfer at Florida Atlantic University, including licensing associate, assistant director, and Interim Assistant Vice President for Research and Director of Technology Transfer.

Mr. Nappi holds a BBA in management and marketing from Florida Atlantic University, MBA coursework in finance, and is a member of the AUTM and LES. He serves on the Board of Directors of BioStrategy Partners.

[back to top]

Brian P. O'Shaughnessy, Shareholder, RatnerPrestia
Brian P. O'Shaughnessy, Shareholder, RatnerPrestia, Washington, DC, is a registered patent attorney with over 25 years' experience in patent law.  He works with innovators in establishing global IP portfolios and in structuring IP-related transactions; and he routinely represents clients before the federal courts, the International Trade Commission, and in post-issuance proceedings at the US Patent and Trademark Office.

Brian is Regional Vice President, USA, of the Licensing Executives Society (USA & Canada), Inc., and has served on the LES Board of Trustees since 2007.  As Regional Vice President, he is responsible for coordinating the Society's statements on legislation, administrative policy, and trends in the law in the U.S.  He is a contributing author and faculty member of the LES Professional Development Series. 

[back to top]

Deanna Okun, Partner, Adduci, Mastriani & Schaumberg, formerly Commissioner, ITC
Deanna OkunDeanna Tanner Okun is a partner of Adduci Mastriani & Schaumberg, LLP, an international trade law firm based in Washington, DC.  Ms. Okun has extensive experience as a top administrator, regulator, enforcer, legislative aide and lawyer. She served two terms as Chairman during her twelve years of service as a member of the ITC, an independent federal agency that provides trade expertise to both the legislative and executive branches of government, determines the impact of imports on U.S. industries and directs enforcement actions against unfair trade practices, such as patent, trademark and copyright infringement.  Her practice steers companies through the intersection where innovation confronts barriers, such as intellectual property theft, unfair trade practices or regulatory hurdles. In 2012, she was named the Outstanding Woman of the Year by the Association of Women in International Trade, a chapter of the Organization of Women in International Trade.  Prior to beginning her career at the ITC, she served as counsel for International Affairs to U.S. Senator Frank Murkowski, Chairman of the Energy and Natural Resources Committee and senior member of the Finance and Foreign Relations Committees.  Ms. Okun received her J.D. from Duke University School of Law, with Honors.

[back to top]

Niklas Östman, Senior Director, IP Licensing, Microsoft
Niklas OstmanBefore joining Microsoft a year ago, Niklas Östman was the Head of Patent Licensing for Nokia Corporation playing a key role in creating the largest patent licensing program ever by a European company. Earlier in his career, he has worked both in-house and as a partner at a top Nordic law firm. Regarding patent licensing specifically, he has negotiated hundreds of patent licenses ranging from multi-billion dollar deals to royalty free ones and from those covering one patent only to those covering up to 460.000 patents globally. He has also extensive dispute resolution experience ranging from multi-billion infrastructure arbitration to ground breaking IPO liability litigation. As to patent litigation, he has been involved in patent lawsuits in the UK, Germany, France, Italy, the Netherlands, Sweden, Finland, Norway, US (TX, VA, CA, WI, DE and US ITC), South Korea, Taiwan as well as in China (Beijing and Shanghai). He has also acted as a trial counsel in patent cases in Finland obtaining several land mark decisions on issues such as the doctrine of equivalence (non-literal infringement), availability of preliminary injunctions and patents for biochemical synthesis routes."

[back to top]

John Paul, Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
John PaulJohn Paul is a partner at the law firm of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP and chairs the firm's IP management and transaction section. With over 30 years of experience in licensing, litigation, and prosecution, he focuses on strategic planning, complex transactions, due diligence investigations, and licensing and enforcement of IP portfolios.

Mr. Paul has analyzed numerous patent portfolios, helped companies understand and effectively communicate the legal and commercial significance of IP portfolios, developed more robust portfolios aligned with business objectives, set up and directed licensing and enforcement programs that generated significant revenue for leading technology companies, and conducted multiple-round private auctions to sell patent portfolios by monetizing portfolios.  He has led the IP due diligence investigations and negotiations in strategic acquisitions of patent portfolios and various complex transactions.

Mr. Paul serves as counsel to the LES board and previously served as a trustee and vice president. He frequently lectures and writes on patent law, licensing, and IP management.

[back to top]

Judith Paul, Manager, Technology Contracts, FMC Technologies, Inc.
Judith PaulJudith Paul is a Contracts Manager with FMC Technologies, Inc.  In her current role, she supports development of intellectual asset program strategies and product development agreements with customers and contractors .  Judith develops intellectual asset strategies and coaches the engineering community on implementation of the adopted strategies as the technology moves beyond R&D and into commercialisation.

Judith has over 17 years experience in drafting, negotiating, and managing contracts and agreements in the oil & gas industry. She has extensive training and experience specific to interface with internal and external parties to negotiate collaboration terms and develop strategic mechanisms for bringing new technology developments to market.

Judith previously worked for various globally focused oil & gas service contractors and operators.

Ms. Paul earned her B.A. – Business Management (Summa Cum Laude) and her M.B.A. – Project Management at American InterContinental University.

[back to top]

Ruth Plager, President, ZenithBIO
Ruth PlagerRuth's track record of adding value to the positioning and ultimate successful commercialization of innovative therapies is built on 30 years of commercial and business development experience both within and for biopharmaceutical companies.

At ZenithBIO (ZB) LLC, Ruth's business consulting and strategic marketing services provide a valuable bridge between life science innovation and business development. Our insightful assessments coupled with our business development network translate to an increase in the value of innovative discovery platforms, technologies and therapies for biopharmaceutical companies. In more than a decade of consulting, Ruth has been retained to spearhead a diverse range of projects designed to increase the value of assets and to accelerate the partnering process.

[back to top]

Ellen Purpus, Director, The Children's Hospital of Philadelphia
Ellen PurpusDr. Ellen Purpus has been the Director of CHOP's Office of Technology Transfer since 2007 and has nearly 20 years' experience in the field. Her areas of expertise include protection and commercialization of biomedical discoveries, creation of academic-industry collaborations, and mentoring newcomers to the field of technology transfer .

Dr. Purpus is a frequent AUTM speaker and was the overall Chair for AUTM's TOOLS , Basic Licensing (now Essentials of Academic Licensing), and Startup and Business Development courses for six years. She is currently co-chair of AUTM's Essentials of Academic Licensing course.

Dr. Purpus earned her PhD in Pathology and Cell Biology from Thomas Jefferson University in Philadelphia, PA and held a post-doctoral fellowship at the National Cancer Institute of the National Institutes of Health.

[back to top]

Gerald Quirk, Esq., Partner, Choate Hall & Stewart,
Gerald QuirkGerald is a partner and co-chair of the life sciences practice group at Choate Hall & Stewart LLP in Boston, representing life sciences companies of all stages in structuring and negotiating strategic transactions such as joint ventures, collaborations and IP licenses. Prior to joining Choate, Gerald was Vice President of Corporate Affairs and General Counsel at Infinity Pharmaceuticals and Managing Corporate Counsel at Genzyme Corporation and began his career in the biotechnology practice group of Palmer & Dodge LLP in Boston. In those roles, Gerald successfully completed numerous transactions to obtain access to novel drug discovery platforms. Gerald holds a JD from Northeastern University, an Ed.M. from Harvard University, and a BA from Swarthmore College.

[back to top]

Arti Rai, Elvin R. Latty Professor of Law, Duke University School of Law (Formerly Administrator of the USPTO Office of External Affairs)
Arti RaiArti Rai, Elvin R. Latty Professor of Law, is an internationally recognized expert in intellectual property (IP) law, administrative law, and health policy. Rai has also taught at Harvard, Yale, and the University of Pennsylvania law schools. Rai's research on IP law and policy in biotechnology, pharmaceuticals, and software has been funded by NIH, the Kauffman Foundation, and the Woodrow Wilson Center. Her publications have appeared in both peer-reviewed journals and law reviews, including Science, the New England Journal of Medicine, the Journal of Legal Studies, Nature Biotechnology, and the Columbia, Georgetown, and Northwestern law reviews. She is the editor of Intellectual Property Law and Biotechnology: Critical Concepts (Edward Elgar, 2011) and the co-author of a 2012 Kauffman Foundation monograph on cost-effective health care innovation.

From 2009-2010, Rai served as the Administrator of the Office of External Affairs at the U.S. Patent and Trademark Office (USPTO). As External Affairs Administrator, Rai led policy analysis of the patent reform legislation that ultimately became the America Invents Act and worked to establish the USPTO's Office of the Chief Economist. Prior to that time, she had served on President-Elect Obama's transition team reviewing the USPTO. Prior to entering academia, Rai clerked for the Honorable Marilyn Hall Patel of the U.S. District Court for the Northern District of California; was a litigation associate at Jenner & Block (doing patent litigation as well as other litigation); and was a litigator in the U.S. Department of Justice's Civil Division.

Rai regularly testifies before Congress and relevant administrative bodies on IP law and policy issues and regularly advises federal agencies on IP policy issues raised by the research that they fund. She is a member of the National Advisory Council for Human Genome Research and of an Expert Advisory Council to the Defense Advanced Projects Research Agency (DARPA). Rai is currently co-chair of the IP Committee of the Administrative Law Section of the ABA. In 2011, Rai won the World Technology Network Award for Law.

Rai graduated from Harvard College, magna cum laude, with a B.A. in biochemistry and history (history and science), attended Harvard Medical School for the 1987-1988 academic year, and received her J.D., cum laude, from Harvard Law School in 1991.

[back to top]

Richard Rainey, Executive Counsel, IP Litigation, GE
Richard RaineyRichard L. Rainey is Executive Counsel, IP Litigation for the General Electric Co. and head of GE's IP Litigation Center of Excellence.  The IP Litigation COE oversees all of GE's IP litigation around the world.  Prior to joining GE, Mr. Rainey was a partner in the Washington, DC office of Covington & Burling LLP.  He has been lead counsel in a number of patent infringement and other intellectual property matters before district courts and the ITC.  Mr. Rainey has also handled more than 40 appeals before the Federal Circuit.  Mr. Rainey has been listed in Chambers for Intellectual Property litigation, Super Lawyers, Best Lawyers in America, and Legal 500.  Before entering private practice, he served as a law clerk to Judge McKelvie at the District of Delaware and Chief Judge Rader at the Federal Circuit.  Mr. Rainey is a co-author of Court of Appeals for the Federal Circuit: Practice and Procedure.  He graduated with High Honors from the George Washington University Law School, where he was a Senior Editor of The George Washington Law Review and member of the Order of the Coif.  Mr. Rainey also holds an undergraduate degree in mechanical engineering from MIT. 

[back to top]

Matthew J. Raymond, PhD, MBA CLP, Director of Intellectual Property, Rush University Medical Center
Matthew J. RaymondDr. Raymond is an experienced business development professional with the responsibility for managing the technology transfer and industry outreach functions at Rush University Medical Center in Chicago. Matt trained in technology transfer at the University of Virginia and The University of Chicago. He is a co-founder of two biomedical companies and has been actively involved at various stages in several dozen others, including as an angel investor. Matt initially worked as an Investigator in discovery and clinical development roles for SmithKline Beecham Animal Health where he was a lead inventor on US and international patents. He received his PhD in Biochemistry/Molecular Biology from the University of Wyoming, completed a postdoctoral fellowship in Ophthalmology and Cell Biology at Yale University School of Medicine and holds the MBA from the University of Virginia's Darden Graduate School of Business. He is a registered Patent Agent with the USPTO.

[back to top]

Stephen Reily, Managing Director & Chairman, IMC
Stephen ReilyStephen Reily is Managing Director, Chairman and General Counsel of IMC (www.imcpartnerships.com). Looking for a way to connect his legal background with a passion for new products, in 1997 Stephen co-founded IMC as a brand licensing agency that has represented major companies like Kraft Foods, S.C. Johnson, Wrigley, and AT&T and dozens of iconic brands like Dole, Valvoline, Philosophy, Milk-Bone, and TABASCO. IMC now develops new product strategies, partnerships through licensing and other transactions, retail development and influencer marketing programs for new products. Stephen publishes articles on these topics and has been an award-winning speaker at leading industry events focused on consumer products and licensing. A former corporate attorney, Stephen graduated from Yale College, summa cum laude, and from Stanford Law School, after which he clerked for Justice John Paul Stevens of the U.S. Supreme Court. He lives in Louisville, Kentucky, with his wife and three children.

[back to top]

Michael Risch, Professor of Law, Villanova University School of Law
Michael RischProfessor Michael Risch joined the Villanova faculty as Associate Professor of Law in 2010 from the West Virginia University College of Law, where he directed the Entrepreneurship, Innovation and Law Program. Prior to joining the West Virginia faculty, he served as an Olin Fellow in Law at Stanford Law School. Professor Risch’s teaching and scholarship focus on intellectual property and cyberspace law, with an emphasis on patents, trade secrets and information access.  His articles have been published in the Stanford Law Review, and the Indiana Law Journal, among others; online in the Yale Law Journal Online andPENNumbra; and less formally at the Madisonian, Prawfsblawg, and Patently-O blogs. Two of his articles have been cited by the United States Supreme Court. Professor Risch received his A.B. with honors and distinction in Public Policy and with distinction in Quantitative Economics from Stanford University, and his J.D. with high honors from the University of Chicago Law School. Prior to entering academia, he was a partner at intellectual property boutique Russo & Hale LLP in Palo Alto, California.

[back to top]

Eric Risser, Vice President, Business Development, Macrogenics
Eric RisserEric Risser has over 15 years of strategy and transaction experience across both small biotechnology and large pharmaceutical companies. During his career, he has led multiple major transactions in the pharmaceuticals area, including company acquisitions, divestments, equity financings, product licenses and research collaborations. He currently leads the business development activities at MacroGenics, and was responsible for the execution of MacroGenics' existing partnerships with Gilead, Servier, Pfizer, Boehringer lngelheim, and Green Cross. Prior to joining MacroGenics, he served as Executive Director, Business Development at Johnson & Johnson Pharmaceuticals, which he joined in 2003. Before Johnson & Johnson, Mr. Risser started and built a successful consulting practice that provided counsel to emerging life science companies in the United States and Europe. He has also worked as a venture capitalist with BankAmerica Ventures and as an investment banker with Lehman Brothers, where he began his career in their New York and London offices. Mr. Risser holds an M.B.A. from Stanford University and a B.A. from Yale University.

[back to top]

Kathy Rosa, President, Shenandoah Consulting Services, LLC
Kathy RosaKathy Rosa received her B.S. in Chemistry from James Madison University and applied what she learned there to many fields. Initially, she worked as a laboratory chemist in environmental and pharmaceutical R&D and had a great time programming a robotic system to perform pharmaceutical analyses. From the R&D lab, she moved into a more customer facing role as a product specialist for Shimadzu Scientific Instruments troubleshooting instrumentation problems and providing training and demonstrations. She then started a consulting business to continue supporting clients with their laboratory instrumentation and set up a new training center for her previous employer. Her consulting company was hired by IBM to develop training for their salespeople on how to demonstrate some of their software products. These assignments led to a full time position with IBM which lasted for 16 years across many roles. Since 2005, Kathy has been responsible for commercializing intellectual property for IBM's Global Services division. For the last 5 years, Kathy led a global team and commercialized 250+ pieces of software for IBM.

In April 2013, Kathy started Shenandoah Consulting Services to provide direction and assistance to other companies in their efforts to commercialize their IP. She looks forward to applying and adapting methods and techniques learned and from many projects for each client so they can make the most of their IP investments.

[back to top]

Juli Saitz, Managing Director, FTI Consulting
Juli SaitzJuli Saitz is a Managing Director in FTI's Forensic Practice in New York.  Ms. Saitz has over fifteen years of experience in providing forensic accounting and financial and economic analysis to attorneys in litigation.  Her responsibilities include managing all aspects of Forensic engagements, including planning, conducting fieldwork, reporting and contract administration.  Ms. Saitz specializes in commercial damages matters with a focus on Intellectual Property (patent, trademark, trade secret and copyright) engagements and has significant experience providing financial consulting services relating to financial analysis and damage analysis in a variety of industries including financial services, apparel, retail, consumer products, manufacturing and entertainment.  Ms. Saitz has issued expert reports and provided expert testimony on behalf of both plaintiffs and defendants.  She has performed financial analyses relating to profit calculations, additional cost claims, incremental profit analysis, apportionment analyses, licensing and royalty determinations, manufacturing and marketing capacity, fixed and variable cost analysis, allocation of costs, evaluation of forecasts and projections and product line profitability. Ms. Saitz also serves a leader in the firm's royalty compliance practice area.

[back to top]

Ed Saltzman, President and Founder, Defined Health
Ed SaltzmanEd is President of Defined Health, a leading business development strategy consultancy to the life sciences. Ed advises senior industry executives on business development and disease area strategy.

Prior to founding Defined Health, Ed held positions at the Ayerst Laboratories unit of American Home Products and at FIND/SVP.

Ed is a well regarded and in demand speaker on industry issues. He has addressed hundreds of industry audiences over the past 20 years. In addition, Ed regularly presents targeted strategy briefings and conducts discussions privately with scores of boards of directors, executive management committees and licensing and business development groups at large pharma, specialty pharma and biotech companies.

Ed is a member of the Licensing Executives Society and the New York Pharma Forum and is a graduate of New York University.

[back to top]

Julie Samuels, Staff Attorney and The Mark Cuban Chair to Eliminate Stupid Patents, Electronic Frontier Foundation
Julie SamuelsJulie Samuels is a Staff Attorney at the Electronic Frontier Foundation, where she also holds the Mark Cuban Chair to Eliminate Stupid Patents. She focuses on intellectual property issues. Before joining EFF, Julie litigated IP and entertainment cases in Chicago at Loeb & Loeb and Sonnenschein Nath & Rosenthal. Prior to becoming a lawyer, Julie spent time as a legislative assistant at the Media Coalition in New York and as an assistant editor at the National Journal Group in D.C. She was also an intern at the National Center for Supercomputing Applications. Julie earned her J.D. from Vanderbilt University and her B.S. in journalism from the University of Illinois at Urbana-Champaign.

[back to top]

George Schoen, Partner, Cravath, Swaine & Moore
George F. Schoen is a partner in Cravath's Corporate Department. His practice focuses primarily on mergers, acquisitions and joint ventures, including hostile and contested transactions. He also regularly counsels corporations and their directors on fiduciary duty and corporate governance matters.

Mr. Schoen was recognized for his Corporate/M&A work by Chambers USA: America's Leading Lawyers for Business from 2011 through 2013. He was also recognized by The Legal 500 for his work in mergers and acquisitions in 2009, 2010, 2012 and 2013; for his transactional work in the telecoms and broadcast industry from 2010 through 2012; and for his transactional work in the technology industry from 2011 through 2013.

Mr. Schoen also serves on the Mergers, Acquisitions & Corporate Control Committee of the New York City Bar Association.

[back to top]

Ekkehard Schoettle, Senior Counsel, BP America
Ekkehard is presently Senior Counsel, Global IP Licensing at BP. In his present role Ekkehard has responsibilities with respect to all intellectual property aspects of  major licensing in and out transactions, M&A transactions, joint ventures, joint development and research transactions across BP’s downstream businesses including refining, chemicals, and lubricants. In previous roles at BP, Ekkehard was the single point of accountability for intellectual property matters for BP’s refining business and BP’s alternative energy businesses. Ekkehard has a B.S.E and M.S.E., both in chemical engineering, from the University of Michigan, Ann Arbor, Michigan and a J.D. from DePaul University College of Law, Chicago, IL.

[back to top]

Jeffrey M. Sears, Associate General Counsel and Chief Patent Counsel, Columbia University
Jeffrey SearsJeffrey M. Sears serves as Associate General Counsel and Chief Patent Counsel for Columbia University.  His practice encompasses all aspects of patent law, including portfolio management, strategic counseling, licensing and post-licensing compliance, litigation, and legislative and regulatory patent matters.

Jeff holds an S.B. in physics from MIT, an M.A. and Ph.D. in physics from SUNY Stony Brook, and a J.D. from NYU.  He is admitted to practice law in New York and before the U.S. Patent and Trademark Office.

[back to top]

Gail Shulman, Former General Counsel, MIPS Technologies, Inc.
Gail ShulmanGail Shulman is former General Counsel for MIPS Technologies where she negotiated the sale of the company in a unique transaction involving the sale of certain patent assets to Bridge Crossing (a subsidiary of Allied Security Trust) and of the operating business to Imagination Technologies. Her responsibilities as general counsel included a broad range of intellectual property, corporate and commercial matters, including legal issues arising in licensing, international operations, mergers and acquisitions, employment, finance and facilities. Before joining MIPS Technologies in 1999, Ms. Shulman was the first in-house lawyer—establishing the legal department—for Axil Computer (a subsidiary of Hyundai Electronics). She also worked for Thelen, Reid, Brown, Raysman & Steiner for more than seven years, where she specialized in corporate matters, licensing and mergers and acquisitions.

Ms. Shulman received her J.D. from the University of California, Hastings College of the Law; and her B.A. from the University of California, San Diego.

She has presented various topics for the Practicing Law Institute, Women in Law Empowerment Forum and Center for Applied Innovation.  She serves on the advisory board for Blaze Mobile.

[back to top]

Laura Silva, Director, IP, Legal, and Licensing, Velocys, Inc.
Laura SilvaLaura is an experienced licensing executive with overall responsibility for all intellectual property and legal activity for Velocys, the technology innovator for smaller-scale gas-to-liquids processing for synthetic fuels. A founding member of Velocys, she led the acquisition and in-licensing of the company's large, pioneering patent portfolio, established multi-million dollar development projects for advancing its platform technology, and directed Velocys' first sale of licensed technology. In 2008, she was part of the Velocys team awarded an R&D100 award for the Velocys microchannel Fischer Tropsch Reactor. Prior to joining Velocys, Laura served as a Commercialization Manager at Battelle's Pacific Northwest National Laboratories, and as a process design engineer with Chevron. Laura has a B.S. and an M.S. in Chemical Engineering from Washington State University and is a registered professional engineer in the state of Washington.

[back to top]

Robin Sitver, Sr. Director Business Development, Johnson & Johnson Consumer Companies, Inc.
Robin Sitver is Senior Director, Business Development at Johnson & Johnson Consumer Products Company. She is primarily responsible for divestiture transactions and innovative transactions related to transformational business activities. She is also responsible for the character trademark licensing program. Previously, she led licensing, acquisition, divestitures, strategic alliances and other business development transactions for the global Topical Health, Intimate Health and Personal Care businesses.

Robin joined J&J in 2006 with the acquisition of Pfizer Consumer Healthcare. She started her career at Pfizer in 1979 in the Pharmaceuticals Division and held a variety of positions in finance, systems, marketing and international operations in the Pharmaceuticals and Animal Health Divisions before joining Pfizer Consumer Healthcare in 2001. She has been involved with over forty license, acquisition and divestiture transactions. Most recently she led the divestitures of Stayfree, Carefree and ob in North America to Energizer, REACH manual toothbrush to Dr. Fresh, Caladryl, Cortaid, AMBI, Purpose, Cornhuskers and Shower to Shower to Valeant, Rolaids to Chattem and Monistat to Insight Pharmaceuticals. She also divested 5 iconic brands including Efferdent to Blacksmith Brands, LLC, secured the license to a complete portfolio of Disney properties for adhesive bandages and other topical health products and directed all aspects of numerous licensing transactions.

Robin is an active member of the Licensing Executives Society. She is a Certified Licensing Professional and has served LES  in a number of leadership roles. For the past several years, she was co-chair of the Consumer Products Sector. She is currently co-chair of the Trademark Licensing Committee.

Robin holds an MBA in Accounting and Decision Sciences from the Wharton School of the University of Pennsylvania and a BA in Computer Science from Brandeis University.

[back to top]

Jim Skippen, President and Chief Executive Officer, Wi-LAN Inc.
Jim SkippenJim Skippen is President and Chief Executive Officer of Wi-LAN Inc. ("WiLAN") and is a member of WiLAN's Board of Directors.  Since assuming this position in June 2006, Mr. Skippen has led WiLAN's licensing efforts which have generated record revenues and patent licensing agreements with over 265 companies, including agreements with technology leaders Broadcom, Fujitsu, Intel, LG, Motorola Mobility, Nokia, Panasonic, RIM and Samsung.   A seasoned licensing executive, Mr. Skippen has managed several large and complex patent licensing negotiations and litigations.  Prior to joining WiLAN, he worked for two of Canada's largest law firms and held a number of senior management positions, including Senior VP Patent Licensing and General Counsel at MOSAID Technologies.  While leading the patent licensing program at MOSAID, he closed deals worth hundreds of millions of dollars.

[back to top]

Catherine Angell Sohn, Pharm.D., President, Sohn Health Strategies
Cathy SohnCatherine Angell Sohn, Pharm.D., C.L.P. currently serves on the Board of Directors of Jazz Pharmaceuticals (NASDAQ: JAZZ), Landec Corp (NASDAQ: LNDC), Dohmen (privately held life science services company) and the World Affairs Council of Philadelphia.  Previously, over 28 years at GlaxoSmithKline, she held U.S. and global leadership roles in the Pharmaceutical, Vaccine and Consumer Healthcare divisions, retiring in 2010 as Sr. Vice President of Worldwide Business Development for GSK Consumer Healthcare, where she led a series of US, European, Japanese and global acquisitions and licensing deals which generated over $2 billion in revenue. Dr. Sohn concurrently serves on the Dean's Advisory Council for Drexel University School of Public Health, the Ben Franklin Technology Partners Investment Advisory Committee, and Springboard Enterprises Life Science Council.  Dr. Sohn received the Distinguished Alumnus Award from UCSF in 2000; was named Woman of the Year by the Healthcare Businesswomen's Association in 2003; received the LES Frank Barnes Mentor Award in 2009; and the HBA Euro Excellence Award in 2012.  Dr. Sohn holds a Doctor of Pharmacy degree from UCSF School of Pharmacy, a Certificate of Professional Development from the Wharton School, is a Certified Licensing Professional and NACD Governance Fellow.

[back to top]

Erich Spangenberg, Owner, IP Navigation Group
Erich SpangenbergErich Spangenberg, the founder of IP Navigation Group (IPNav), has advised patent owners in hundreds of enforcement, acquisition, commercialization and monetization transactions. 

Prior to founding IPNav, Erich was a partner at the law firm of Jones Day (corporate), Senior Vice President of Investment Banking at Donaldson, Lufkin & Jenrette, and President of Smartalk Teleservices and also of Acclaim Ventures Group.

In addition to providing IP monetization advisory services through IPNav, Erich owns companies that actively engage in enforcement, acquisition, commercialization and monetization transactions.

Erich holds a BA from Skidmore College (Periclean Scholar), an MSc from the London School of Economics (Distinguished Graduate), and a JD from Case Western Reserve University (Law Review).

[back to top]

Mark Stignani, Of Counsel, Schwegman, Lundberg & Woessner
Mark StignaniMark Stignani is a registered patent attorney and serves as Of Counsel at Schwegman, Lundberg & Woessner, P.A. Mark has patent experience in various technology areas, including software, information systems, mobile devices, computer hardware and design, telecommunications, and mechanical. His practice includes prosecution, post-grant proceedings, patent and portfolio analysis, freedom to operate, patent strategy and planning and strategic counseling. Prior to joining SLW, Mark served as an Assistant General Counsel for Thomson Reuters for over ten years. While at Thomson Reuters, Mark’s responsibilities included the harvesting and protection of intellectual property associated with software and high value content as well as providing primary intellectual property legal support for business development, contracts, editorial, technology area in the legal, healthcare, and financial services information market groups. As an integrated team member, Mark also served on various executive committees that drove investment in acquisitions, emerging business development and new product development across a multiple set of marketplaces. Mark received his Juris Doctorate from William Mitchell College of Law while working for Alliant Techsystems. He had previously done post graduate work in robotics and control systems at the University of Minnesota and National Technological University while working at Honeywell, Inc.

[back to top]

Debora Stewart, Managing Director and Co-Founder, Invotex
Debora StewartDebbie Stewart is a managing director and co-founder of Invotex and head of the firm's License Management and Royalty Compliance practice. With more than 25 years experience, her background also includes management responsibilities for an international consulting firm's intellectual property consulting practice where she managed large engagements in litigation support, forensic accounting and financial investigation services.

Ms. Stewart has worked with corporations, universities and their counsel on intellectual property matters for the majority of her career. She has experience working with a wide range of industries, from computer graphics, pharmaceuticals and biotechnology to consumer goods. Ms. Stewart's experience includes intellectual property compliance, royalty audits, valuation and licensing consulting as well as reasonable royalty and lost profit damage calculations in patent, trademark and copyright infringement and trade secret matters. Ms. Stewart has uncovered in excess of $150 million in underpaid royalties for her clients.

Ms. Stewart is a member of the American Institute of Certified Public Accountants (AICPA), Association of University Technology Managers (AUTM), International Licensing Industry Merchandisers' Association (LIMA), and the Licensing Executives Society (LES). She has authored several articles and is a frequent speaker on licensing and royalty compliance topics.

[back to top]

Hamza Suria, President & CEO, AnaptysBio 
Hamza SuriaMr. Suria joined AnaptysBio in December 2008. Prior to AnaptysBio, Mr. Suria was at Maxygen, where he was responsible for partnering and alliance management of next-generation protein therapeutics with Roche, Sanofi-Aventis, Bayer, Astellas and others. Before Maxygen, Mr. Suria was responsible for business development at Diabetogen Biosciences and Viron Therapeutics. Suria holds a B.Sc. in biochemistry from Kalamazoo College, an M.S. in immunology from the University of Western Ontario and an Executive MBA from the Richard Ivey School of Business.

[back to top]

William Tanenbaum, Partner, Chair, IP and Technology Transactions Group and Green Tech and Sustainability Group, Kaye Scholer
William TanenbaumWilliam Tanenbaum was named as the "Lawyer of the Year 2013" for IT in NY by US News & World Report and Best Lawyers and ranked in Band One in Technology and Outsourcing in NY by Chambers. He is Head of Kaye Scholer’s IP and Technology Practice Group, which was ranked in the First Tier in NY by US News & World Report. He also Heads the firm’s GreenTech and Sustainability Group.  Bill is recognized as an "IP Star," as one of the Top 30 IT Lawyers in the U.S., as a "Life Science Star" and as one of the "CleanTech 100." Bill is a past President of the International Technology Law Association, is currently a VP of SIM (NY), an industry CIO association, and the attorney delegate to the Advisory Board of the SIG, an industry outsourcing association. Bill is a graduate of Brown University and Cornell Law School.

[back to top]

Shashank Upadhye, Partner, Seyfarth Shaw, LLP (Formerly Global Head of IP Apotex Inc. and U.S. Head of IP Sandoz
Shashank UpadhyeShashank Upadhye, a partner in the Chicago office of Seyfarth Shaw, LLP devotes his practice to the pharmaceutical and medical devices fields, where he advises clients in all matters related to intellectual property (portfolio building, transactions, and litigation), regulatory affairs, strategies on maximizing assets, antitrust, and corporate governance, on the brand and generic sides. A globally recognized expert in the pharmaceutical space, he was V.P.- Global Head of l.P:for Apotex, Inc., in Toronto, Canada, where he built the Apotex legal department and managed all aspects of l.P., regulatory affairs law, antitrust, and aligning legal functions with the other corporate functions. Prior, he was V.P. - Head of l.P. for Sandoz, Inc., in Princeton, NJ; and for Eon Labs, Inc., in Long Island. Shashank is a prolific author as he writes the pharmaceutical industry's leading legal treatise entitled, Generic Pharmaceutical Patent and FDA Law (West/Thomson Reuters) and 10 other full length law review articles.

[back to top]

Guy Van Meter, Vice President, Head of Business Development, Adimab
Mr. Guy Van Meter has been Head of Business Development at Adimab, LLC since October, 2008. Prior thereto, Mr. Van Meter served at Pfizer Inc., in a business development role where he was involved in new business initiatives around RNAi therapeutics and regenerative medicine for Pfizer's Biotherapeutics and Bioinnovation Center in San Francisco. He spent 6 years in business development at Dyax Corp., including managing Dyax's successful phage display licensing program. Prior to Dyax, Mr. Van Meter conducted research at Harvard's Brigham and Women's and Yale University. He graduated from the Olin Graduate School of Business at Babson College in 2002.

[back to top]

Allen Vaughn, Manager of IP Strategy and Licensing, Lockheed Martin
Allen Vaughn is the Manager of Intellectual Property Strategy and Licensing for Lockheed Martin and is responsible for the Missiles and Fire Control Business Sector. Allen has been the Chairman of the Intellectual Property review board for the last 18 years to determine the best means of protecting the Sector's intellectual assets.  Further he is responsible for all licensing of technologies. His efforts have resulted in Lockheed Martin both in and out licensing of technologies which is the majority of all transaction of the entire corporation.  He has been active in LES for over a decade, and is the former chairman of the High Technology sector and the Aerospace and Defense Committee.

[back to top]

David J. Wallan, Director, Intellectual Property and Licensing, DuPont
David WallanDave is responsible for intellectual property and trade secret risk management as well licensing and joint development activities in the Packaging and Industrial Polymers Strategic Business Unit of DuPont in Wilmington, DE. A 34 year veteran of the company, he has held variety research and technology management positions prior to assuming his current role in 2004. Originally from upstate NY, he obtained a BS in Chemistry from St John Fisher College and a PhD in Analytical Chemistry from the University of Michigan. A golfer and tennis player, he and his wife are avid sailors and spend much of their free time on their boat "Horizon" in Rock Hall, MD on the Chesapeake Bay.

[back to top]

Aric Weiker, Director, Business Development and Strategy, Microsoft
Aric WeikerAric joined Microsoft in 1995 and worked as a Geographer and Program Manager before moving to Business Development. His specialty is inbound technology licensing. He works closely with product development teams to identify gaps in features or functionality that can be procured as IP from third parties. Aric architects and negotiates commercial licenses and his current focus areas are the Dynamics ERP and CRM products from the Business Solutions Division.

Aric's previous work included deals for Microsoft's Platforms group, Consumer Division, Unified Communications technologies and Server Management products.

Aric holds a Bachelor's degrees in Environmental Conservation and Journalism from the University of Colorado and an MBA in Technology Management from the University of Washington.

[back to top]

Jeffrey Whittle Partner, Bracewell & Giuliani LLP
Jeff WhittleJeffrey Whittle is a technology and intellectual property attorney with the international law firm of Bracewell & Giuliani LLP, where he is the International Head of the Technology Law Section. He has experience representing clients in various technology-based transactions, including licenses, agreements for technology development, transfer, acquisition, joint development, product development, strategic alliance, collaboration, and product distribution, as well as various other intellectual property agreements in the software, e-commerce, energy, telecommunications, cloud computing, big data, mechanical/electrical, financial, and medical industries. Jeff is member of the Board of Trustees of LES (USA & Canada), Vice President of LES (USA & Canada) for Education, an International Delegate to LES (USA & Canada), co-chair of the Education Committee for LES International, and a frequent speaker and author, nationally and internationally, on various licensing and technology topics. He is listed in Chambers USA America's Leading Lawyers for Business, Intellectual Property, Legal 500 Patent Prosecution: Litigation and Design Patents/Technology: Transactions, IAM Licensing 250: The World's Leading Patent & Technology Licensing Lawyers, and IAM Patent 1000: The World's Leading Patent Practitioners. Jeff is a graduate of Vanderbilt University (BEEE) and Wake Forest University (MBA, JD). He is also on the Board of Visitors for Wake Forest University School of Law. He is a Certified Licensing Professional (CLP), is licensed to practice law in Texas, New York, Florida, and North Carolina, and before numerous federal district and appellate courts, including the Federal Circuit Court of Appeals and U.S. Supreme Court, and is licensed to practice before the U.S. Patent and Trademark Office.

[back to top]

Nick Widnell, Deputy Assistant Director, Bureau of Competition's Anticompetitive Practices Division, Federal Trade Commission
Nick WidnellNicholas A. Widnell is a Deputy Assistant Director of the Anticompetitive Practices Division of the Federal Trade Commission.  He manages antitrust investigations covering a wide variety of unilateral and coordinated conduct in diverse industries ranging from industrial inputs and services to consumer products.  Nick recently managed the investigation of Motorola, Inc. and Google, in which Google agreed that it would not seek injunctions on standard essential patents without first agreeing to either a court or arbitration proceeding to determine a reasonable and nondiscriminatory license.  Prior to joining the Commission, Nick worked in the antitrust group at Collier Shannon Scott and clerked for the Honorable E. Grady Jolly of the United States Court of Appeals for the Fifth Circuit.

[back to top]

Clint Wilder, Senior Editor, Clean Edge, Co-author, Clean Tech Nation
Clint WilderClint Wilder is senior editor at leading clean-tech research and advisory firm Clean Edge and the coauthor of two books, Clean Tech Nation: How the U.S. Can Lead in the New Global Economy (HarperCollins, 2012) and The Clean Tech Revolution (HarperCollins, 2007). Forbes says Clean Tech Nation "makes a convincing case that technologies under the clean tech umbrella have migrated from the margins to the mainstream of America's energy economy." A recognized expert on current trends in clean-energy technology, policy, and finance, Wilder is a frequent speaker at clean-tech and green business events in the U.S. and overseas and a blogger for The Huffington Post.

[back to top]

Michael Williams, Team Lead, Commercial Sectors LNG for Transport, Shell Americas
Michael Williams is the Team Lead, Commercial Sectors in Shell's LNG for Transport division, where he is responsible for commercial strategy, market development and successful deal delivery across the LNG for Transport in the Americas.  Michael, who is based out of Houston, serves as a project lead for a wide range of the division's ongoing commercial efforts to help generate a new diversified energy future that includes cleaner, more efficient transportation fuels.  Prior to joining Shell, Michael served as an investment principal, focused on real estate, energy and infrastructure, for various private investment concerns in Europe, the Middle East region and Sub- Saharan Africa.  Michael, a native of New Haven, Connecticut, is a Henry Luce Scholar in Law and International Development and earned degrees in law, social science and business from Morehouse College, Yale University, Columbia Law School and the Stanford Graduate School of Business.

[back to top]

Scott Williams, Director, Invotex Group
Scott WilliamsScott Williams is a Director with Invotex Group . He is responsible for managing the sale and licensing of clients' intellectual property assets as well as providing consulting services related to both litigation and the valuation of intellectual property and technology businesses. He has more than 20 years experience in licensing and business development as well as in consulting to technology businesses. Over the past twelve years, he has specialized in intellectual property assets.

Prior to joining Invotex, Mr. Williams served as Vice President in the Strategic Business Development and Technology Commercialization business units of BTG plc, a British technology investment and development company. He also served as Director of Sales and Marketing for a start-up manufacturer of industrial computers and plant floor workstations where he was responsible for building a national distribution network and developing strategic partnerships with private label resellers and OEMs.

Mr. Williams is a Certified Licensing Professional and a Certified Valuation Analyst. He has authored several articles and is a frequent speaker on licensing and IP valuation topics.

[back to top]

Timothy K. Wilson, Senior IP Counsel, SAS Institute
Tim WilsonTim Wilson is Senior IP Counsel in the Legal Division at SAS Institute Inc., the world's largest private software company, where he leads the patent practice.  He also provides advice on all types of intellectual property law matters and competitive intelligence issues.  Prior to joining SAS, Tim was an associate at Brown Raysman in New York, where he advised clients on all manner of licensing and outsourcing transactions.  Tim began his legal career as a patent and intellectual property litigator with Jones Day in Cleveland.  Tim received his JD from Syracuse University College of Law in 1992 and a BS from Pennsylvania State University in 1989. Tim is a member of the Editorial Board of Intellectual Property Magazine.

[back to top]

David Woodle, CEO and Chairman, NanoHorizons
David WoodleRecognized strategic, success-oriented international business leader with over 30 years proven experience at publicly and privately-held technology companies as Chief Executive, key corporate manager, and Board member. Specialized and comprehensive expertise in strategic planning and implementation, technical innovation, public offerings, acquisitions, corporate restructuring, and value enhancement for small and large businesses.


[back to top]

Barbara Yanni, Vice President and Chief Licensing Officer, Merck
Barbara YanniBarbara Yanni is Vice President and Chief Licensing Officer of Merck . She leads the Corporate Licensing group which is responsible for negotiating agreements to acquire compounds, programs and new technologies to complement Merck's research programs and pipeline. Barbara works closely with her scientific and marketing colleagues at Merck to ensure that the company has access to discoveries that will enhance Merck's ability to bring new medicines to the market.

Previously, Barbara was Executive Director of Corporate Development where she negotiated acquisitions, divestitures and other business arrangements. Barbara has also worked in other positions in Finance including Financial Evaluation and Analysis, Treasury and Tax. She joined Merck in 1985 as Domestic Tax Counsel after working as a tax lawyer at Bristol-Myers and in private practice. Barbara graduated from Stanford Law School and Wellesley College. She also holds a Masters of Law in Taxation from New York University.

[back to top]